Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 21036. Отображено 100.
05-01-2012 дата публикации

Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy

Номер: US20120003229A1
Принадлежит: Individual

The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

Подробнее
19-01-2012 дата публикации

Compounds for the prevention and treatment of cardiovascular diseases

Номер: US20120015905A1
Автор: Henrik C. Hansen
Принадлежит: Resverlogix Corp

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Подробнее
26-01-2012 дата публикации

Pyrrolidine triple reuptake inhibitors

Номер: US20120022125A1
Автор: Jianguo Ma, Liming Shao
Принадлежит: SUNOVION PHARMACEUTICALS INC

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Подробнее
01-03-2012 дата публикации

Azafluorene derivative and organic light-emitting device using the derivative

Номер: US20120049176A1
Принадлежит: Canon Inc

A novel azafluorene derivative and an organic light-emitting device having the derivative are provided. The organic light-emitting device includes a pair of electrodes composed of an anode and a cathode one of which is a transparent or semi-transparent electrode, and an organic compound layer interposed between the pair of electrodes. The organic compound layer contains the azafluorene derivative represented by the following general formula (I):

Подробнее
08-03-2012 дата публикации

Carbazole and carboline kinase inhibitors

Номер: US20120058988A1
Принадлежит: Bristol Myers Squibb Co

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Подробнее
29-03-2012 дата публикации

Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof

Номер: US20120077982A1

The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.

Подробнее
12-04-2012 дата публикации

Five-membered heterocycles useful as serine protease inhibitors

Номер: US20120088758A1
Принадлежит: Bristol Myers Squibb Co

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Подробнее
12-04-2012 дата публикации

Azole derivatives and fused bicyclic azole derivatives as therapeutic agents

Номер: US20120088778A1
Принадлежит: vTvx Holdings I LLC

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Подробнее
19-04-2012 дата публикации

Novel Heterocyclic Compounds as Pesticides

Номер: US20120094837A1
Принадлежит: Bayer CropScience AG

The present invention relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which include arthropods and especially insects.

Подробнее
17-05-2012 дата публикации

Compounds and compositions comprising cdk inhibitors and methods for treating cancer

Номер: US20120121692A1

Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents, and methods for preparing the disclosed antitumor agents.

Подробнее
07-06-2012 дата публикации

Light-emitting device material and light-emitting device

Номер: US20120138907A1
Принадлежит: TORAY INDUSTRIES INC

Embodiments provide a light emitting device material characterized by containing an anthracene compound represented by the following general formula. where R 19 to R 37 are a hydrogen atom, alkyl group, cycloalkyl group, heterocyclic group or the like; n is 1 or 2; and A is a heteroarylene group or arylene group. Any one of the R 19 to R 27 and any one of the R 28 to R 37 are used for linking with A. The present teachings allow a light emitting device having high luminous efficiency and excellent durability.

Подробнее
07-06-2012 дата публикации

Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor

Номер: US20120142666A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of the formula (I), (II) and (III) which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
07-06-2012 дата публикации

Bicyclic compound

Номер: US20120142714A1
Принадлежит: Takeda Pharmaceutical Co Ltd

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Подробнее
07-06-2012 дата публикации

Heteroaryls and uses thereof

Номер: US20120142732A1
Принадлежит: Millennium Pharmaceuticals Inc

This invention provides compounds of formula IA or IB: wherein HY, R 1 , R 2 , and G 1 , are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Подробнее
14-06-2012 дата публикации

Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Номер: US20120149637A1
Принадлежит: Individual

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Подробнее
19-07-2012 дата публикации

Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors

Номер: US20120184505A1
Принадлежит: Individual

In its many embodiments, the present invention provides a novel class of pyrimidine analogs as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention also includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the cell cycle checkpoint modulator as well as combinations and pharmaceutical kits. An example cell cycle checkpoint modulator is shown below: formula (I).

Подробнее
26-07-2012 дата публикации

Treatment or prophylaxis of proliferative conditions

Номер: US20120190639A1
Принадлежит: UNIVERSITY OF DUNDEE

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

Подробнее
09-08-2012 дата публикации

Compounds for the treatment of hepatitis c

Номер: US20120201783A1
Принадлежит: Bristol Myers Squibb Co

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Подробнее
09-08-2012 дата публикации

Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)

Номер: US20120202795A1
Принадлежит: Aventis Pharmaceuticals Inc

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R 1 , R 2 , R 3 and R 4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Подробнее
09-08-2012 дата публикации

Dual small molecule inhibitors of cancer and angiogenesis

Номер: US20120202800A1
Автор: Milton L. Brown

The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.

Подробнее
16-08-2012 дата публикации

Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors

Номер: US20120208817A1
Автор: Jian Qiu, Xicheng Sun
Принадлежит: N30 Pharmaceuticals Inc

The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

Подробнее
16-08-2012 дата публикации

4-(Substituted Anilino)-Quinazoline Derivatives Useful as Tyrosine Kinase Inhibitors

Номер: US20120208833A1
Принадлежит: Qilu Pharmaceutical Co Ltd

The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.

Подробнее
27-09-2012 дата публикации

Process for the preparation of lapatinib and its pharmaceutically acceptable salts

Номер: US20120245351A1
Принадлежит: Natco Pharma Ltd

The present invention relates to an improved and new process for the preparation of high purity crystalline base of Lapatinib of formula (1) having chemical name N-{3-chloro-4-[(3-fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl]-2-furyl]-4-quip-azolinamine and its pharmaceutically acceptable salts.

Подробнее
11-10-2012 дата публикации

Novel antiplatelet agent

Номер: US20120258951A1
Принадлежит: Mitsubishi Tanabe Pharma Corp

The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: wherein, X is N, or CR 1d , X b1 -X b5 are the same or different, and are nitrogen or carbon, R 1a -R 1d are the same or different, and are hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted alkylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino, R 2 is an optionally substituted aryl or an optionally substituted heteroaryl, R 3 is an optionally substituted aryl or an optionally substituted heteroaryl, or pharmaceutically acceptable salt thereof as an active ingredient.

Подробнее
01-11-2012 дата публикации

Aromatic heterocyclic derivative and organic electroluminescence device using the same

Номер: US20120273766A1
Принадлежит: Idemitsu Kosan Co Ltd

An aromatic heterocyclic derivative represented by the following formula (1), a material for an organic electroluminescence device and an organic electroluminescence device including these:

Подробнее
08-11-2012 дата публикации

Novel benzofurane-piperidine compounds

Номер: US20120283254A1
Принадлежит: Hoffmann La Roche Inc

The present invention is concerned with novel selective dual modulators of the 5-HT 2A and D 3 receptors of formula (I) wherein R 1 , R 2 , R 3 , n, and Y are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as pharmaceuticals.

Подробнее
08-11-2012 дата публикации

Use of rylene derivatives as photosensitizers in solar cells

Номер: US20120283432A1

Use of rylene derivatives I with the following definition of the variables: X together both —COOM; Y a radical -L-NR 1 R 2   (y1) -L-Z—R 3   (y2) the other radical hydrogen; together both hydrogen; R is optionally substituted (het)aryloxy, (het)arylthio; P is —NR 1 R 2 ; B is alkylene; optionally substituted phenylene; combinations thereof; A is —COOM; —SO 3 M; —PO 3 M 2 ; D is optionally substituted phenylene, naphthylene, pyridylene; M is hydrogen; alkali metal cation; [NR 5 ] 4 + ; L is a chemical bond; optionally indirectly bonded, optionally substituted (het)arylene radical; R 1 , R 2 are optionally substituted (cyclo)alkyl, (het)aryl; together optionally substituted ring comprising the nitrogen atom; Z is —O—; —S—; R 3 is optionally substituted alkyl, (het)aryl; R′ is hydrogen; optionally substituted (cyclo)alkyl, (het)aryl; R 5 is hydrogen; optionally substituted alkyl (het)aryl; m is 0, 1, 2; n, p m=0: 0, 2, 4 where: n+p=2, 4, if appropriate 0; m=1: 0, 2, 4 where: n+p=0, 2, 4; m=2: 0, 4, 6 where: n+p=0, 4, 6, or of mixtures thereof as photosensitizers in solar cells.

Подробнее
15-11-2012 дата публикации

Certain Compounds, Compositions and Methods

Номер: US20120289475A1
Принадлежит: Eisai Inc

The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.

Подробнее
06-12-2012 дата публикации

Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Номер: US20120309787A1

The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Подробнее
20-12-2012 дата публикации

Condensed-cyclic compound and organic light emitting diode comprising the same

Номер: US20120319086A1
Принадлежит: Samsung Mobile Display Co Ltd

A condensed-cyclic compound and an organic light-emitting diode including the same.

Подробнее
27-12-2012 дата публикации

Inhibitors of hepatitis c virus ns5b polymerase

Номер: US20120328569A1
Принадлежит: Individual

Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Подробнее
03-01-2013 дата публикации

3-alkoxy, thioalkyl and amino-4-amino-6-(substituted)picolinates and their use as herbicides

Номер: US20130005574A1

3-alkoxy, thioalkyl and amino-4-amino-6-(substituted)picolinic acids having a halogen, alkyl or mono-, di- tri- and tetra-substituted aryl substituents in the 6-position, and their acid derivatives, are herbicides demonstrating a broad spectrum of weed control.

Подробнее
03-01-2013 дата публикации

Pyrazole derivatives as protein kinase modulators

Номер: US20130005702A1
Принадлежит: Cancer Research Technology LTD

The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

Подробнее
14-02-2013 дата публикации

Novel benzodioxole piperazine compounds

Номер: US20130040948A1
Принадлежит: Hoffmann La Roche Inc

The present invention is concerned with novel dual modulators of the 5-HT 2A and D 3 receptors of formula (I) wherein n, Y, R 1 , R 2 , R 3 , and R 4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions containing them and their use as pharmaceutical agents.

Подробнее
14-02-2013 дата публикации

Multisubstituted aromatic compounds as inhibitors of thrombin

Номер: US20130040950A1
Принадлежит: Verseon Corp

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

Подробнее
28-02-2013 дата публикации

2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives

Номер: US20130053381A1
Принадлежит: NOVARTIS AG

The invention relates to a 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivative being (A) a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; or (B) a compound selected from a certain group of 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivatives disclosed in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them. In a first aspect, the invention provides prodrugs of AMPA receptor antagonists which potentially useful in the treatment of a wide range of disorders, particularly epilepsy.

Подробнее
07-03-2013 дата публикации

Methods of identifying modulators of gpr17

Номер: US20130059899A1

The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Подробнее
21-03-2013 дата публикации

PROLYL HYDROXYLASE INHIBITORS

Номер: US20130072487A1
Принадлежит: GlaxoSmithKline LLC

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) 2. The method according to wherein:X is O;Y is O;{'sup': 1', '4, 'sub': 1-', '10', '2-', '10', '2-', '10', '3', '8', '3', '8', '1-', '10', '5', '8', '5', '8', '1-', '10', '3', '8', '3', '8', '1-', '10', '1-', '10', '1-', '10, 'Rand Rare each independently selected from the group consisting of hydrogen, CCalkyl, CCalkenyl, CCalkynyl, C-Ccycloalkyl, C-Ccycloalkyl-CCalkyl, C-Ccycloalkenyl, C-Ccycloalkenyl-CCalkyl, C-Cheterocycloalkyl, C-Cheterocycloalkyl-CCalkyl, aryl, aryl-CCalkyl, heteroaryl and heteroaryl-CCalkyl;'}{'sup': 2', '7', '8', '9, 'Ris —NRRor —OR;'}{'sup': '3', 'sub': 1-', '4, 'claim-text': [{'sup': 7', '8, 'sub': 1-', '10', '2-', '10', '2-', '10', '3', '8', '3', '8, 'where Rand Rare each independently selected from the group consisting of hydrogen, CCalkyl, CCalkenyl, CCalkynyl, C-Ccycloalkyl, C-Cheterocycloalkyl, aryl and heteroaryl, and'}, {'sup': '9', 'sub': 1-', '10', '3', '6, 'Ris H or a cation, or CCalkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C-Ccycloalkyl, heterocycloalkyl, aryl and heteroaryl,'}, {'sup': 1', '2', '3', '4', '7', '8', '9', '10', '5', '6', '10', '10', '10', '10', '10', '5', '6', '5', '6', '5', '10', '5', '10', '5', '6', '5', '5', '6', '5', '6', '5', '10', '5', '6', '10, 'sub': 1', '6', '1', '6', '2', '2', '2', '2', '10', '2', '10', '3', '6', '3', '6', '1', '6', '1', '6', '1-', '10', '2-', '10', '2-', '10', '1', '4', '3', '6', '3', '6', '2', '1', '4', '3', '8', '3', '8', '6', '14', '1-', '10', '1-', '10, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'where any carbon or heteroatom of R, R, R, R, R, R, Ris unsubstituted or is substituted with one or more substituents independently selected from C-Calkyl, C-Chaloalkyl, halogen, —OR, —NRR, oxo, cyano, nitro, —C(O)R, —C(O)OR, —SR, —S(O)R, —S(O)R, —NRR, —CONRR, —N(R)C(O)R, —N(R)C(O)OR, —OC(O) ...

Подробнее
28-03-2013 дата публикации

NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS

Номер: US20130079361A1
Принадлежит:

Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula (I): wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions comprising a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions, comprising administering a safe and effective amount of a Formula I compound. 2. The compound of selected from the group set forth in Table 1.3. The compound of claim 1 , wherein X and Y are both N.4. The compound of claim 3 , wherein B is H.5. The compound of claim 1 , wherein A is halo claim 1 , B is A claim 1 , and X and Y are both N.6. The compound of claim 1 , wherein X is N claim 1 , and Y is CH.7. The compound of claim 6 , wherein B is H.8. The compound of claim 1 , wherein X is CH claim 1 , and Y is N.9. The compound of claim 8 , wherein B is H.10. The compound of claim 1 , wherein A is selected from the group consisting of indole claim 1 , quinoline claim 1 , and naphthalene.11. The compound of claim 1 , wherein the compound is 4-Iodo-6-(2-fluorophenyl)pyrimidine or 4-Iodo-6-(3-aminocarbonylphenyl)pyrimidine.13. The pharmaceutical composition of claim 12 , wherein the compound is selected from the group set forth in Table 1.15. The method of claim 14 , wherein the MIF-implicated disease is selected from the group consisting of inflammatory disease and cancer.16. The method of claim 15 , wherein the inflammatory disease is selected from the group consisting of dermatitis claim 15 , arthritis claim 15 , rheumatoid arthritis claim 15 , insulin-dependent diabetes claim 15 , proliferative vascular disease claim 15 , acute respiratory distress syndrome claim 15 , sepsis claim 15 , septic shock claim 15 , psoriasis claim 15 , asthma ...

Подробнее
11-04-2013 дата публикации

NOXIOUS ARTHROPOD CONTROL COMPOSITION AND HETEROCYCLIC COMPOUND

Номер: US20130090353A1
Принадлежит: Sumitomo Chemical Company, Limited

A noxious arthropod controlling composition comprising a heterocyclic compound represented by the formula (1) [wherein, Aand Arepresent ═C(R)—, nitrogen and so on, Rrepresents a halogen and so on, Rand Rrepresent optionally substituted C1 to C4 chain hydrocarbon group and so on, Rrepresents a hydrogen and so on, n represents 0 or 1] as an active ingredient has an excellent effect for controlling noxious arthropods. 2. The noxious arthropod controlling composition according to claim 1 , wherein the heterocyclic compound represented by the formula (1) is a heterocyclic compound wherein Ris hydrogen.3. The noxious arthropod controlling composition according to claim 1 , wherein the heterocyclic compound represented by the formula (1) is a heterocyclic compound wherein Ris hydrogen.4. The noxious arthropod controlling composition according to claim 1 , wherein the heterocyclic compound represented by the formula (1) is a heterocyclic compound wherein Ris hydrogen.5. The noxious arthropod controlling composition according to claim 1 , wherein the heterocyclic compound represented by the formula (1) is a heterocyclic compound wherein Ris a C1 to C6 chain hydrocarbon group optionally substituted with at least one selected from group X claim 1 , —OR claim 1 , —S(O)R claim 1 , —NRR claim 1 , —NRC(O)R claim 1 , —NRCOR claim 1 , —C(O)R claim 1 , —C(NOR)R claim 1 , —COR claim 1 , —CONRR claim 1 , —CONRNRR claim 1 , a cyano group claim 1 , a nitro group claim 1 , a halogen claim 1 , or hydrogen claim 1 ,{'sup': 7', '8', '7', '7', '9, 'sub': 'm', 'Rand Rare the same or different, and each are a C1 to C6 chain hydrocarbon group optionally substituted with at least one selected from group X or hydrogen (wherein when m in —S(O)Ris 1 or 2, Rrepresents a C1 to C6 chain hydrocarbon group optionally substituted with at least one selected from group X), and Ris a C1 to C6 chain hydrocarbon group optionally substituted with at least one selected from group X.'}6. The noxious arthropod ...

Подробнее
18-04-2013 дата публикации

2-(substituted phenyl)-6-amino-5-alkoxy, thioalkoxy and aminoalkyl-4-pyrimidinecarboxylates and their use as herbicides

Номер: US20130096005A1
Принадлежит: DOW AGROSCIENCES LLC

2-(Substituted phenyl)-6-amino-5-alkoxy, thioalkoxy and aminoalkyl-4-pyrimidinecarboxylic acid and its derivatives are potent herbicides demonstrating broad spectrum of weed control.

Подробнее
25-04-2013 дата публикации

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Номер: US20130102597A1
Принадлежит: INTERMUNE, INC.

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. 3. The method of claim 2 , wherein{'sup': '1', 'Ris selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cyano, sulfonamido, halo, alkenylenearyl, and heteroaryl;'}{'sup': 2', '2', '1, 'sub': 3', '2', '2', '2', '2', '2, 'Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo, unsubstituted alkyl, alkenyl, OCF, NO, CN, NC, OH, alkoxy, haloalkoxy, amino, COH, and COalkyl; haloalkylcarbonyl; cycloalkyl; hydroxylalkyl; sulfonamide; unsubstituted cycloheteroalkyl and cycloheteroalkyl substituted with one to three substituents independently selected from alkyleneOH, C(O)NH, NH, aryl, haloalkyl, halo, and OH; or Rand Rtogether form an optionally substituted 5-membered nitrogen-containing heterocyclic ring;'}{'sup': '4', 'Ris selected from the group consisting of hydrogen, haloalkyl, alkoxy, alkenyl, and alkenylenearyl; and'}{'sup': '5', 'Xis hydrogen.'}4. The method of claim 1 , wherein one of X claim 1 , X claim 1 , and Xis not hydrogen.5. The method of claim 4 , wherein Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo claim 4 , unsubstituted alkyl claim 4 , alkenyl claim 4 , OCF claim 4 , NO claim 4 , CN claim 4 , NC claim 4 , OH claim 4 , alkoxy claim 4 , haloalkoxy claim 4 , amino claim 4 , COH ...

Подробнее
02-05-2013 дата публикации

1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS

Номер: US20130109685A1
Принадлежит: ACTELION PHARMACEUTICALS LTD.

The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), 2. The compound according to claim 1 , whereinX represents —O— or a bond;Y represents methandiyl;Z represents O;n represents 0 or 1;{'sup': '1', 'claim-text': [{'sub': 1', '2', '1', '2, '(C-C)alkyl which is mono-substituted with optionally substituted aryl, optionally substituted heteroaryl or optionally substituted aryl-(C-C)alkoxy; or'}, 'cyclopropyl which is mono-substituted with optionally substituted aryl;, 'Rrepresents'}{'sup': '2', 'Rrepresents hydrogen, trifluoromethyl or fluoro;'}{'sup': '3', 'Rrepresents hydrogen or fluoro;'}{'sup': '4', 'Rrepresents hydrogen;'}{'sup': '5', 'Rrepresents halogen or cyano;'}{'sup': '6', 'Rrepresents hydrogen;'}{'sup': '7', 'Rrepresents hydrogen; and'}{'sup': '10', 'Rrepresents —C(O)OH;'}or a salt thereof.3. The compound according to claim 1 , whereinX represents —O—;or a salt thereof.4. The compound according to claim 1 , whereinX represents a bond;or a salt thereof.5. The compound according to claim 1 , whereinZ represents O;or a salt thereof.6. The compound according to claim 1 ,wherein{'sup': '1', 'claim-text': [{'sub': 1', '4', '3', '6', '1', '2', '1', '2, '(C-C)alkyl which is mono-substituted with (C-C)cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted aryl-(C-C)alkoxy or optionally substituted heteroaryl-(C-C)alkoxy; or'}, {'sub': 1', '4, 'cyclopropyl which is mono- or di-substituted with (C-C)alkyl, mono-substituted with optionally substituted aryl or mono-substituted with optionally substituted heteroaryl;'}], 'Rrepresents'}or a salt thereof.7. The compound according to claim 1 , wherein{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4, 'Rrepresents hydrogen, (C-C)alkyl, (C-C)alkoxy, (C-C)fluoroalkyl or halogen;'}or a salt thereof.8. The compound according to claim 1 , ...

Подробнее
02-05-2013 дата публикации

ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

Номер: US20130109686A1
Принадлежит:

The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 2. The compound of wherein W is pyridyl claim 1 , and pharmaceutically acceptable salts thereof.3. The compound of wherein W is phenyl claim 1 , and pharmaceutically acceptable salts thereof.4. The compound of wherein R is Ccycloalkyl optionally substituted with 1 to 3 groups of R claim 1 , and pharmaceutically acceptable salts thereof.5. The compound according to wherein R is cyclohexyl or cyclohexenyl claim 4 , both optionally substituted with 1 to 3 groups of R claim 4 , and pharmaceutically acceptable salts thereof.6. The compound of wherein R is (CHR)Cheterocycle claim 1 , optionally substituted with 1 to 3 groups of R claim 1 , and pharmaceutically acceptable salts thereof.7. The compound according to wherein R is pyranyl claim 6 , tetrahydropyranyl claim 6 , or pyridyl claim 6 , all optionally substituted with 1 to 3 groups of R claim 6 , and pharmaceutically acceptable salts thereof.8. The compound according to wherein R is (CHR)Caryl claim 1 , optionally substituted with 1 to 3 groups of R claim 1 , and pharmaceutically acceptable salts thereof.9. The compound according to wherein R is phenyl optionally substituted with 1 to 3 groups of R claim 8 , and pharmaceutically acceptable salts thereof.15. A compound of formula (I) of which is found in Table 1 as well as those listed immediately below:2-[(1S,2S)-2-Hydroxycyclohexyl]-5-(4-methoxybenzyl)-1,2-dihydro-3H-benzo[e]isoindol-3-one;2-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-methylpyridin-3-yl)methyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one,2-[(1S ...

Подробнее
09-05-2013 дата публикации

3-aminopyrrolidine derivatives as modulators of chemokine receptors

Номер: US20130116230A1
Принадлежит: Incyte Corp

The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

Подробнее
09-05-2013 дата публикации

IRE-1alpha INHIBITORS

Номер: US20130116247A1
Принадлежит: MANNKIND CORPORATION

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies. 114-. (canceled)16. A product comprising a compound of , wherein the product is selected from the group consisting of (a) a pharmaceutical composition comprising the compound of and a pharmaceutically acceptable vehicle; and (b) a complex comprising IRE-1α and the compound of .17. A method of inhibiting IRE-1α activity claim 15 , comprising contacting IRE-1α with a compound of or a prodrug or pharmaceutically acceptable salt thereof.18. The method of wherein the IRE-1α activity is selected from the group consisting of cleavage of RNA claim 17 , cleavage of mRNA claim 17 , RNA splicing claim 17 , and mRNA splicing.19. The method of wherein the IRE-1α activity is cleavage of mRNA and wherein the mRNA is selected from the group consisting of Blos1 mRNA claim 18 , DGAT2 mRNA claim 18 , CD59 mRNA claim 18 , and IRE-1α mRNA.20. The method of claim 18 , wherein the IRE-1α activity is inhibited to treat a disorder associated with the unfolded protein response claim 18 , comprising administering to a patient in need thereof the compound of or the prodrug or pharmaceutically acceptable salt thereof.21. The method of further comprising administering a therapeutic agent that induces or up-regulates IRE-1α expression.2202. The method of claim further comprising administering a therapeutic agent which is less effective when IRE-1α is expressed.23. The method of claim 20 , further comprising administering to the patient a proteasome inhibitor.24. The method of claim 20 , wherein the IRE-1α activity is inhibited to treat a disorder associated with a target of regulated IRE 1-dependent decay (RIDD) claim 20 , comprising administering to a patient in need ...

Подробнее
16-05-2013 дата публикации

2-Thiopyrimidinones

Номер: US20130123230A1
Принадлежит:

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions. 111.-. (canceled)12. The compound 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3 ,4-dihydropyrimidin-1(2H)-yl)acetamide or a pharmaceutically acceptable salt thereof.13. (canceled)15. A method of treating cardiovascular conditions comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug.16. A method as recited in wherein the cardiovascular condition is heart failure claim 15 , congestive heart failure claim 15 , peripheral arterial disease claim 15 , pulmonary hypertension or vasculitis.17. A method as recited in wherein the mammal has unstable angina or has experienced myocardial infarction.18. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier claim 12 , vehicle or diluent.19. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:{'claim-ref': {'@idref': 'CLM-00012', 'claim 12'}, 'a first compound, said first compound being a compound of , a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;'}a second compound, said second compound being an angiotensin converting enzyme inhibitor, a HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, a Factor Xa inhibitor or warfarin; anda pharmaceutical carrier, vehicle or diluents.2029.-. (canceled) This nonprovisional application claims priority from U.S. Provisional Application No. 61/558,605, filed on Nov. 11, 2011.This invention relates to compounds that are myeloperoxidase inhibitors, pharmaceutical compositions ...

Подробнее
16-05-2013 дата публикации

Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Номер: US20130123257A1
Принадлежит: Merck Patent GmBH

The present invention relates to quinoxalinone derivatives of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in claim as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated. 124.-. (canceled)26. A method according to claim 25 , wherein the compound induces insulin secretion in response to glucose concentration.27. A method according to claim 25 , for the treatment of diabetes.28. A method according to claim 27 , for the treatment of type II diabetes.29. A method according to claim 25 , for the treatment of dyslipidaemia or obesity30. A method according to claim 25 , for the treatment of diabetes related microvascular or macrovascular complications.31. A method according to claim 30 , wherein the complications include arterial hypertension claim 30 , atherosclerosis claim 30 , inflammatory processes claim 30 , microangiopathy claim 30 , macroangiopathy claim 30 , retinopathy or neuropathy.32. A method according to claim 25 , for the reducing hyperglycaemia.33. A method according to claim 25 , wherein R1 is: alkyl claim 25 , cycloalkyl claim 25 , cycloalkylalkyl claim 25 , heterocycloalkyl claim 25 , heterocycloalkylalkyl claim 25 , alkyloxyalkyl claim 25 , R7R8N-alkyl or alkylthioalkyl; wherein the heterocycloalkyl groups have one or more heteroatom selected from N claim 25 , O and S; and wherein each of these groups is optionally substituted by one or more groups selected from Y or Z.34. A method according to claim 25 , wherein R1 is: methyl claim 25 , ethyl claim 25 , butyl claim 25 , cyclopropyl or cyclopropylmethyl; wherein each of these groups is optionally substituted by one or more groups selected from Y or Z.35. A method according to claim 25 , wherein R1 is: 2 claim 25 ,2-difluoroethyl or 2 claim 25 ,2 claim 25 ,2-trifluoroethyl.36. A method according to claim 25 , wherein R6 is: alkyl claim 25 , aryl ...

Подробнее
16-05-2013 дата публикации

SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONES AND DERIVATIVES THEREOF AS KINASE INHIBITORS

Номер: US20130123259A1
Принадлежит: ALLERGAN, INC.

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. 2. The compound of wherein A is a carbocyclic aryl group.3. The compound of wherein A is a heterocyclic aryl group.4. The compound of wherein Ris a carbocyclic aryl group.5. The compound of wherein Ris a heterocyclic aryl group.6. The compound of wherein N(R) is selected from the group consisting of pyrrolidine claim 1 , 3-fluoropyrrolidine claim 1 , piperidine claim 1 , 4-fluoropiperidine claim 1 , N-methylpiperazine claim 1 , morpholine claim 1 , 2 claim 1 ,6-dimethylmorpholine claim 1 , thiomorpholine wherein said heterocyclic ring may be substituted with one or more of R.7. A method for treating diseases related to unregulated tyrosine kinase signal transduction claim 1 , the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of .8. The method of wherein said disease is selected from the group consisting of cancer claim 7 , blood vessel proliferative disorders claim 7 , fibrotic disorders claim 7 , mesangial cell proliferative disorders and metabolic diseases.9. The method of wherein the blood vessel proliferative disorder is selected from the group consisting of diabetic retinopathy claim 8 , age-related macular degeneration claim 8 , retinopathy of prematurity claim 8 , arthritis and restenosis.10. The method of wherein the fibrotic disorder is selected from the group consisting of hepatic cirrhosis and atherosclerosis.11. The method of wherein the mesangial cell proliferative disorder is selected from the group consisting of glomerulonephritis claim 7 , diabetic nephropathy claim 7 , malignant nephrosclerosis claim 7 , thrombotic microangiopathy syndromes claim 7 , transplant rejection and glomerulopathies.12. The method of wherein the metabolic disorder is selected from the group consisting of psoriasis ...

Подробнее
23-05-2013 дата публикации

Novel Estrogen Receptor Ligands

Номер: US20130131061A1
Принадлежит: KARO BIO AB

The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R, R, R, Rand Rare as defined in the specification. 125.-. (canceled)27. A method as claimed in claim 26 , in which each Ris independently selected from the group consisting of hydrogen claim 26 , Calkyl claim 26 , Calkenyl claim 26 , Calkynyl claim 26 , Ccycloalkyl claim 26 , phenyl and benzyl.28. A method as claimed in claim 27 , in which each Rindependently represents hydrogen or Calkyl.29. A method as claimed in claim 26 , in which each Ris independently selected from the group consisting of hydrogen and Calkyl.30. A method as claimed in claim 26 , in which is selected from the group consisting of OR claim 26 , N(R) claim 26 , —C(O)Calkyl claim 26 , Calkyl claim 26 , Calkenyl claim 26 , Calkynyl claim 26 , haloCalkyl claim 26 , dihaloCalkyl claim 26 , trihaloCalkyl claim 26 , haloCalkenyl claim 26 , dihaloCalkenyl claim 26 , trihaloCalkenyl claim 26 , phenyl claim 26 , and 5-6 membered heterocyclyl claim 26 , wherein said phenyl or heterocyclyl group can either be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of OR claim 26 , halogen claim 26 , cyano claim 26 , —C(O)Calkyl claim 26 , Calkyl claim 26 , Calkenyl claim 26 , Calkynyl claim 26 , haloCalkyl claim 26 , dihaloCalkyl and trihaloCalkyl.31. A method as claimed in claim 30 , in which Ris selected from the group consisting of OR claim 30 , N(R) claim 30 , —C(O)Calkyl claim 30 , Calkyl claim 30 , Calkenyl claim 30 , Calkynyl claim 30 , phenyl claim 30 , and 5-6 membered heterocyclyl claim 30 , wherein said phenyl or ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
30-05-2013 дата публикации

HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Номер: US20130136794A1
Принадлежит: PEKING UNIVERSITY

Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer. 2. The compound according to claim 1 , wherein the group A is substituted or unsubstituted heterocyclic group claim 1 , is the heterocyclic group being selected from pyridyl claim 1 , pyrimidinyl claim 1 , pyrazinyl claim 1 , furyl claim 1 , oxazolyl claim 1 , pyrazolyl claim 1 , thiazolyl or oxadiazolyl; preferably the group A is substituted or unsubstituted pyridyl claim 1 , or pyridyl fused with benzene or morpholine ring claim 1 , the fused benzene or morpholine ring being unsubstituted or substituted with methyl.3. The compounds according to claim 2 , wherein the Calkyl is methyl claim 2 , the Calkoxy is methoxy claim 2 , the Calkoxycarbonyl is methoxycarbonyl claim 2 , and/or the Calkylamido is pentylamido .4. The compound according to claim 3 , wherein the Rgroup is cyano.5. The compound according to claim 1 , wherein the compound is:3-(furan-2-ylmethyl)-4-hydroxy-1,3-thiazinane-2-thione (compound 1);2-(methoxycarbonyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 2);2-cyanoethyl(furan-2-ylmethyl)dithiocarbamate (compound 3);3-(furan-2-ylmethyl)-4-hydroxy-4,5-dimethyl-3,4-dihydro-2H-1,3-thiazine-2-thione (compound 4);2-sulfamoylethyl(furan-2-ylmethyl)dithiocarbamate (compound 5);2-boronoethyl(furan-2-ylmethyl)dithiocarbamate (compound 6);2-(methylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 7);2-(benzylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 8);4-hydroxy-3-(pyridin-3-ylmethyl)-1,3-thiazinane-2-thione ( ...

Подробнее
30-05-2013 дата публикации

Heterocyclic compound and use thereof

Номер: US20130137675A1
Принадлежит: Takeda Pharmaceutical Co Ltd

The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like. A compound represented by the formula (1 x ): wherein each symbol is as described in the DESCRIPTION, or the formula (1): W 1 —W 2   (1) wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Подробнее
30-05-2013 дата публикации

PYRROLIDINE TRIPLE REUPTAKE INHIBITORS

Номер: US20130137744A1
Автор: MA Jianguo, Shao Liming
Принадлежит: Sunovion Pharmaceutical Inc.

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. 131-. (canceled)44. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.45. A method of inhibiting binding of a monoamine transporter ligand to a monoamine transporter claim 32 , comprising contacting the monoamine transporter with a compound of .46. The method of claim 45 , wherein the monoamine transporter is selected from serotonin transporter (SERT) claim 45 , dopamine transporter (DAT) claim 45 , norepinephrine transporter (NET) and combinations thereof.47. A method of inhibiting the activity of at least one monoamine transporter claim 32 , comprising contacting the monoamine transporter with a compound of .48. The method of claim 47 , wherein the monoamine transporter is selected from serotonin transporter (SERT) claim 47 , dopamine transporter (DAT) claim 47 , norepinephrine transporter (NET) and combinations thereof.49. A method of inhibiting uptake of at least one monoamine by a cell claim 32 , comprising contacting said cell with a compound of .50. The method of claim 49 , wherein the monoamine is selected from serotonin claim 49 , dopamine claim 49 , norepinephrine and combinations thereof.51. The method of claim 49 , wherein the cell is a neuronal cell.52. A method of treating a central nervous system disorder claim 32 , comprising administering to a subject in need thereof ...

Подробнее
06-06-2013 дата публикации

BENZOHETEROCYCLIC ANTI-BACTERIAL AGENTS

Номер: US20130143841A1
Принадлежит: University of Notre Dame du Lac

Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria. 2. A method of treating a drug-resistant bacterial strain , comprising:{'i': 'Staphylococcus aureus', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering a compound to an individual infected with or suspected of being infected with a methicillin-resistant strain, a vancomycin-resistant strain, or a linezolid-resistant strain, a compound of .'} This application is a continuation of U.S. patent application Ser. No. 12/995,437, filed Nov. 30, 2010, which is a continuation of International Application No. PCT/US2009/045737, filed May 29, 2009, which claims priority to U.S. Provisional Patent Application No. 61/057,282, filed May 30, 2008, the entire disclosures of which are hereby incorporated by reference in their entirety.This invention was made with government support under Grant No. R01 AI 054193 awarded by the National Institutes of Health. The United States Government has certain rights in the invention.Embodiments herein relate to anti-bacterial agents, and, more specifically, to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.In 2004, the IDSA (Infectious Disease Society of America) reported that each year 90,000 of the 2 million people who acquire a hospital bacterial infection will die. That is a 4.5% mortality rate arising from just being within the hospital. Multi-drug resistance bacterial strains are a major problem and one that has been increasing very rapidly every year during the last few decades. In brief, from its discovery in 1968 multi-drug resistant (MRSA) had already accounted for greater than 50% of patient isolates by 1999 in ICUs (intensive care units) within ...

Подробнее
06-06-2013 дата публикации

Stem cell differentiating agents and uses therefor

Номер: US20130143935A1
Принадлежит: University of Texas System

The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.

Подробнее
13-06-2013 дата публикации

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Номер: US20130150401A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula I, 2. The compound according to claim 1 , wherein Ris 2-fluoro-2-methylpropyl or (1-trifluoromethylcyclopropyl)methyl.8. A pharmaceutical composition comprising a compound according to and an inert carrier or diluent.9. A method for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119 in a patient in need thereof claim 1 , the method comprising administering to the patient a pharmaceutically effective amount of a compound according to .10. The method according to claim 1 , wherein the disease or condition which are mediated by activating the G-protein-coupled receptor GPR119 is diabetes claim 1 , obesity claim 1 , or dyslipidemia. The present invention relates to new compounds of formula Iwherein R, L, L, X, A and n are defined as hereinafter, to processes for preparing these compounds, to their use as modulators of the G-protein-coupled receptor GPR119, to methods for their therapeutic use, in particular in diseases and conditions mediated by the modulation of the G-protein-coupled receptor GPR119, and to pharmaceutical compositions comprising them.Diabetes mellitus is a serious metabolic disease which affects more than 100 million people worldwide. In the USA there are more than 12 million diabetics with 600,000 new cases diagnosed every year. The prevalence of diabetes mellitus is increasing, resulting in a high frequency of complications and a substantial impairment of quality of life and life expectancy. Because of diabetes-associated microvascular complications, in the industrialised countries type 2 diabetes is currently the most common cause of adult-onset loss of vision, renal insufficiency and amputations. In addition, type 2 diabetes is associated with a two- to five-fold increase in the risk of cardiovascular disease.The UKPDS study (United Kingdom Prospective Diabetes Study) showed that intensive treatment with common therapeutic agents, e.g. ...

Подробнее
20-06-2013 дата публикации

PYRIMIDINE DERIVATIVES AS FAK INHIBITORS

Номер: US20130158005A1

Compounds of the formula (I), in which R, Rand Rhave the meanings indicated in Claim , are kinase inhibitors and can be employed, inter alia, for the treatment of tumours. 2. Compounds according to in which{'sup': 1', '3', '3, 'sub': 2', 'n', '2', '2', 'n', '2', '2', 'n', '2', 'n', '2, 'claim-text': 'and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.', 'Arphenyl which is mono-, di-, tri-, tetra or pentasubstituted by Hal, (CH)CN, SOA, (CH)CONH, (CH)CONHA, (CH)CONA, Hetand/or NHCOHet,'}3. Compounds according to in which{'sup': 2', '4', '5, 'sub': 2', 'n', '2', '2', '2, 'Ardenotes phenyl which is mono-, di-, tri-, tetra or pentasubstituted by Hal, A, (CH)CN, SOA, NHSOA, NA′SOA and/or C(RR)CN,'}and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.4. Compounds according to in which{'sup': '1', 'Hetdenotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl, tetrahydroquinolyl, dihydrobenzoxazolyl, dihydropyridazinyl, dihydrobenzimidazolyl, dihydrobenzothiazolyl, piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, imidazolidinyl, oxazolidinyl or tetrahydropyranyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, CN, NHCOA, COA, OAr and/or ═O,'}and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.5. Compounds according to in which{'sup': 2', '4', '5, 'sub': 2', '2', '2', 'p, 'Hetdenotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl ...

Подробнее
20-06-2013 дата публикации

2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR

Номер: US20130158259A1
Принадлежит: Janssen Pharmaceutica NV

2-Aminopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis. 2. A chemical entity as in claim 1 , wherein Rand Rtaken together form —(CH)—.9. A chemical entity as in claim 1 , wherein Ris H.10. A chemical entity as in claim 1 , wherein Rand Rare each independently H or methyl.11. An chemical entity selected from:4-(4-Methyl-piperazin-1-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;4-(4-piperazin-1-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;(R)-4-(3-Amino-pyrrolidin-1-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;(R)-4-(3-Methylamino-pyrrolidin-1-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;(R,R)-4-(Hexahydro-pyrrolo[3,4-b]pyrrol-5-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;4-(cis-Octahydro-pyrrolo[3,4-b]pyridin-6-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;(R,R)-4-(Octahydro-pyrrolo[3,4-b]pyridin-6-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;(S,S)-4-(2,5-Diaza-bicyclo[2.2.1]hept-2-yl)-5,6,7,8-tetrahydro-quinazolin-2-ylamine;4-(4-Methyl-piperazin-1-yl)-6,7-dihydro-5H-cyclopentapyrimidin-2-ylamine;(R)-4-(3-Methylamino-pyrrolidin-1-yl)-6,7-dihydro-5H-cyclopentapyrimidin-2-ylamine;and pharmaceutically acceptable salts thereof.12. An chemical entity as in claim 1 , wherein said chemical entity is a compound of Formula (I) or a pharmaceutically acceptable salt of said compound of Formula (I). This application is a divisional application of U.S. application Ser. No. 13/043,420 filed on Mar. 8, 2011, which is a divisional application of U.S. application Ser. No. 12/070,051, filed on Feb. 14, 2008, now U.S. Pat. No. 7,923,451, which claims the benefit of U.S. provisional patent application Ser. No. 60/889,798, filed on Feb. 14, 2007. The present application is also a divisional application of U.S. application Ser. No. 13/043,391 ...

Подробнее
20-06-2013 дата публикации

Aminodihydrothiazine derivatives

Номер: US20130158260A1
Принадлежит: Shionogi and Co Ltd

A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene; X is S, O, or NR′; R 1 is a hydrogen atom or lower alkyl; R 2a , R 2b , R 3a , R 3b , R 4a and R 4b is each independently a hydrogen atom, halogen, or hydroxy etc.; n and m are each independently an integer of 0 to 3; n+m is an integer of 0 to 3; R 5 is a hydrogen atom or substituted lower alkyl; its pharmaceutically acceptable salt, or a solvate thereof.

Подробнее
04-07-2013 дата публикации

FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS

Номер: US20130172341A1
Принадлежит:

Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I). 3. The compound of wherein Ris heteroaryl claim 1 , wherein said heteroaryl group is unsubstituted or substituted by one to three Rgroups claim 1 , or alternatively two Rcan optionally be taken together with the carbon atoms to which they are attached to form a five- or six-membered cycloalkyl claim 1 , cycloalkenyl claim 1 , heterocyclyl claim 1 , heterocyclenyl claim 1 , arl or heteroaryl.8. A pharmaceutical composition comprising at least one compound of and a pharmaceutically acceptable carrier.9. A method of treating or preventing cancer in a mammal in need of such treatment that is comprised of administering to said mammal a therapeutically effective amount of a compound of .10. A method of treating cancer or preventing cancer in accordance with wherein the cancer is selected from cancers of the brain claim 9 , genitourinary tract claim 9 , lymphatic system claim 9 , stomach claim 9 , larynx and lung.11. A method of treating or preventing cancer in accordance with wherein the cancer is selected from histiocytic lymphoma claim 10 , lung adenocarcinoma claim 10 , small cell lung cancers claim 10 , pancreatic cancer claim 10 , liver cancer claim 10 , gastric cancer claim 10 , colon cancer claim 10 , multiple myeloma claim 10 , gliobastomas and breast carcinoma.12. A method of using the compound according to for the preparation of a medicament useful in treating or preventing cancer in a mammal in need of such treatment.13. A method of using the compound according to for the preparation of a medicament useful in inhibiting ERK in a mammal in need of such treatment.14. A method of using the compound according to for the preparation of a medicament useful in preventing or modulating metastasis of cancer in a mammal in need of such ...

Подробнее
04-07-2013 дата публикации

2,6-DIHALO-5-ALKOXY-4-SUBSTITUTED-PYRIMIDINES, PYRIMIDINE- CARBALDEHYDES, AND METHODS OF FORMATION AND USE

Номер: US20130172557A1
Принадлежит: DOW AGROSCIENCES LLC

2,6-Dihalo-5-alkoxy-4-substituted-pyrimidines, 2,6-dihalo-5-alkoxy-4-pyrimdine carbaldehydes, and derivatives of each are useful intermediates in forming potent herbicides that demonstrate a broad spectrum of weed control. These compounds are disclosed, as are methods of forming and using these compounds. 2. The compound of in which Xrepresents chlorine.3. The compound of in which Q represents methoxy.4. The compound of in which Rrepresents vinylic.6. The compound of in which Xrepresents chlorine.7. The compound of in which Q represents methoxy.8. A method of farming a 2 claim 5 ,6-dihalo-5-alkoxy-pyrimdine-4-carbaldehyde comprising reacting a 2 claim 5 ,6-dihalo-5-alkoxy-4-substituted pyrimidine with an oxidant.9. The method of wherein reacting a 2 claim 8 ,6-dihalo-5-alkoxy-4-substituted pyrimidine with an oxidant comprises reacting the 2 claim 8 ,6-dihalo-5-alkoxy-4-substituted pyrimidine with ozone.10. The method of wherein reacting a 2 claim 8 ,6-dihalo-5-alkoxy-4-substituted pyrimidine with an oxidant comprises reacting a 2 claim 8 ,6-dichloro-5-methoxy-4-vinylic pyrimidine with ozone to form a 2 claim 8 ,6-dichloro-5-methoxy-pyrimidine-4-carbaldehyde.11. A method of forming a 2 claim 8 ,6-dihalo-5-alkoxy-4-substituted pyrimidine comprising:reacting a 2,6-dihalo-5-alkoxy pyrimidine with an organometallic halide reagent to form a 2,6-dihalo-5-alkoxy-4-substituted-3-(metal-halo or metal) pyrimidine; andoxidizing the 2,6-dihalo-5-alkoxy-4-substituted-3-(metal-halo or metal) pyrimidine to form the 2,6-dihalo-5-alkoxy-4-substituted pyrimidine.12. The method of claim 11 , wherein reacting a 2 claim 11 ,6-dihalo-5-alkoxy pyrimidine with an organometallic reagent comprises reacting a 2 claim 11 ,6-dihalo-5-alkoxy pyrimidine with a Grignard reagent.13. The method of claim 12 , wherein reacting a 2 claim 12 ,6-dihalo-5-alkoxy pyrimidine with a Grignard reagent comprises reacting a 2 claim 12 ,6-dihalo-5-alkoxy pyrimidine with a vinyl magnesium bromide.14. The method of ...

Подробнее
01-08-2013 дата публикации

Substituted 1,3-Dioxanes and There Uses

Номер: US20130197030A1
Принадлежит: EVOLVA SA

The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. 35-. (canceled)719-. (canceled)20. A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors claim 1 , the method comprising: administering to a subject an effective amount of a compound of or acceptable salts claim 1 , N-oxides claim 1 , hydrates claim 1 , or solvates thereof; and a pharmaceutically-acceptable carrier or diluent.21. The method of claim 20 , wherein the disorder is cancer.2228-. (canceled)29. The method according to claim 20 , wherein said disorder is selected from the group consisting of myocardial infarction claim 20 , thrombosis claim 20 , thrombotic disorders claim 20 , pulmonary hypertension claim 20 , atherosclerosis claim 20 , diabetic nephropathy claim 20 , retinopathy claim 20 , peripheral arterial disease claim 20 , lower limb circulation claim 20 , pulmonary embolism claim 20 , thrombus formation claim 20 , stent-triggered thrombus formation claim 20 , stent-triggered hyperplasia hyperplasia claim 20 , septic shock claim 20 , preeclampsia claim 20 , asthma claim 20 , allergic rhinitis claim 20 , tumour angiogenesis and metastasis.3034-. (canceled)35. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable carrier.3639-. (canceled) This application claims the benefit of and claims priority from U.S. provisional Application Ser. No. 60/989,805, filed Nov. 21, 2007, U.S. provisional Application Ser. No. 60/989,806, filed Nov. 21, 2007, U.S. provisional Application Ser. No. 60/989,808, filed Nov. 21, 2007, and PCT Application No. PCT/US07 ...

Подробнее
08-08-2013 дата публикации

Thioacetate compounds, compositions and methods of use

Номер: US20130203779A1
Принадлежит: Ardea Biociences Inc

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Подробнее
08-08-2013 дата публикации

COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM

Номер: US20130203818A1
Принадлежит: CalciMedica, Inc.

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. 111.-. (canceled)1346.-. (canceled)4855.-. (canceled)56. The compound of wherein Lis —NH—C(═O).57. The compound of wherein Ris aryl.58. The compound of wherein aryl is phenyl.59. The compound of wherein the phenyl group is substituted with at least one Rselected from F claim 58 , Cl claim 58 , Br claim 58 , I claim 58 , —CN claim 58 , —OH claim 58 , —CF claim 58 , —OCF claim 58 , —OR claim 58 , —N(R) claim 58 , and C-Calkyl.60. The compound of wherein Ris selected from —CF claim 59 , —OCF claim 59 , —OR claim 59 , C-Calkyl claim 59 , and C-Ccycloalkyl.61. The compound of wherein Ris C-Calkyl.62. The compound of wherein Ris —CFand Ris —CH.63. The compound of wherein n is 1.64. The compound of wherein Ris fluorine.65. The compound of wherein phenyl is substituted with at least 2 substituents.66. The compound of wherein phenyl is substituted with at least 3 substituents.67. The compound of wherein Ris heteroaryl.68. The compound of wherein heteroaryl is selected from thienyl claim 67 , thianthrenyl claim 67 , furyl claim 67 , pyranyl claim 67 , thiadiazolyl claim 67 , benzothiadiazolyl claim 67 , isobenzofuranyl claim 67 , chromenyl claim 67 , xanthenyl claim 67 , phenoxathiinyl claim 67 , pyrrolyl claim 67 , imidazolyl claim 67 , pyrazolyl claim 67 , isothiazolyl claim 67 , isoxazolyl claim 67 , pyridyl claim 67 , pyrazinyl claim 67 , pyrimidinyl claim 67 , pyridazinyl claim 67 , pyrazolo-pyrimidinyl claim 67 , triazolo-pyrimidinyl claim 67 , imidazo-pyrimidinyl claim 67 , indolizinyl claim 67 , isoindolyl claim 67 , 3H-indolyl claim 67 , indolyl claim 67 , indazolyl claim 67 , purinyl claim 67 , 4H- ...

Подробнее
08-08-2013 дата публикации

PYRAZOLE SYNTHESIS BY COUPLING OF CARBOXYLIC ACID DERIVATIVES AND ENAMINES

Номер: US20130204011A1
Автор: GLORIUS FRANK, SURI MAMTA

A method of synthesizing Pyrazoles by means of the oxidative conversion of Enamines with suitable N-containing carboxylic acid derivatives in the presence of copper ions and 2-picolinic acid derivatives is provided. 1. A method comprising:producing Pyrazoles by means of a conversion of Enamines and N-containing carboxylic acid derivatives in the presence of an oxidation agent, copper ions, and 2-picolinic acid (derivatives).2. A method according to claim 1 , wherein the N-containing carboxylic acid derivatives are selected from the group comprising nitriles claim 1 , carboxylic acid amides claim 1 , amidines claim 1 , imidates claim 1 , imidoyl chlorides claim 1 , derived protonated salts of these compounds claim 1 , as well as mixtures thereof.3. A method according to claim 1 , wherein the conversion is carried out in the presence of Cu(II) salts claim 1 , and a ratio of Enamine to Cu(II) salt ranges from ≧1.5:1 to ≦30:1 (mol Cu(II) salt: mol Enamine).4. A method according to claim 1 , wherein a ratio of 2-picolinic acid (derivatives) to Enamine ranges from ≧0.01% to ≦10% (mol/mol).5. A method according to claim 1 , wherein a nitrile is selected as the N-containing carboxylic acid derivative and the conversion is carried out in this nitrile as a solvent.6. A method according to claim 1 , wherein a ratio of Enamine to N-containing carboxylic acid derivative ranges from ≧0.2:1 to ≦150:1 (mol N-containing carboxylic acid derivative: mol Enamine). The following relates to the field of organic synthesis, especially the field of heterocycle synthesis.Heterocyclic compounds play an immense role in organic chemistry, especially in active ingredients and pharmaceuticals, and the synthesis of heterocyclic compounds represents an important and steadily growing field of research.Pyrazoles represent an important class of heterocycles. Pyrazoles occur relatively rarely in natural materials but are an important structural element in biologically active compounds, which in some ...

Подробнее
15-08-2013 дата публикации

2-quinolinyl-acetic acid derivatives as hiv antiviral compounds

Номер: US20130210801A1
Принадлежит: Gilead Sciences Inc

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

Подробнее
15-08-2013 дата публикации

Novel cortistatin a analog and use thereof

Номер: US20130210859A1
Принадлежит: Osaka University NUC

A compound represented by the general formula (M): (wherein R 1 represents a substituted or unsubstituted aromatic heterocyclic group, R 2 represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 3 carbon atoms, OR 3 , N(R 3 ) 2 , C(═O)OR 3 or C(═O)N(R 3 ) 2 , R 3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 4 carbon atoms, R 4 represents a hydrogen atom, an oxygen atom or OR 5 , and R 5 represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, or an acyl group having 1 to 3 carbon atoms); or a pharmaceutically acceptable salt thereof is a cortistatin A analog which is useful as an active ingredient of medicaments for cancer prevention or treatment in that the analog can be mass-produced by chemical synthesis due to its simple chemical structure and retains the same biological activities as those of cortistatin A.

Подробнее
22-08-2013 дата публикации

SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS

Номер: US20130217650A1
Принадлежит: ALLERGAN, INC.

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. 16-. (canceled)812-. (canceled)13. A method of treating a disease selected from the group consisting of diabetic retinopathy , age-related macular degeneration , retinopathy of prematurity , arthritis , restenosis , hepatic cirrhosis , atherosclerosis , glomerulonephritis , diabetic nephropathy , malignant nephrosclerosis , thrombotic microangiopathy syndromes , transplant rejection glomerulopathies , psoriasis , diabetes mellitus , wound healing , and inflammation , the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of at least one compound selected from the group consisting ofMethyl 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoate,2-{[(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoic acid,2-{[(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}-N-methylbenzamide, andN-(3-{[(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]amino}phenyl)acetamide.151. The method of claim , wherein said disease is age-related macular degeneration.16. The method of claim 13 , wherein said disease is age-related macular degeneration.17. The method of claim 14 , wherein said disease is age-related macular degeneration. This application is a divisional of U.S. application Ser. No. 11/625,856, filed Jan. 23, 2007 which claims the benefit of U.S. Provisional Application No. 60/761,660, filed Jan. 24, 2006, which is expressly incorporated herein by reference in its entirety.1. Field of the InventionThe present invention relates to novel compounds capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. The present invention is ...

Подробнее
22-08-2013 дата публикации

PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Номер: US20130217700A1
Принадлежит: ARENA PHARMACEUTICALS, INC.

Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HTreceptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-IITserotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together. 2. (canceled)423.-. (canceled)26. The compound according to selected from the group consisting of:2-[4-(1,5-Dimethyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-ethanone;(4-Bromo-1-methyl-1H-pyrazol-3-yl)-{4-[2-(4-chloro-phenyl)-ethyl]-piperazin-1-yl}-methanone;1-(4-Fluoro-phenyl)-2-[4-(2-methyl-5-phenyl-2H-pyrazole-3-carbonyl)-piperazin-1-yl]-ethanone;2-[4-(4-Bromo-2,5-dimethyl-2H-pyrazole-3-carbonyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-ethanone;5-{2-[4-(4-Bromo-1-methyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl]-ethyl}-6-chloro-1,3-dihydro-indol-2-one;2-[(S)-4-(4-Chloro-1-methyl-1H-pyrazole-3-carbonyl)-3-methyl-piperazin-1-yl]-1-(4-fluoro-phenyl)-ethanone;2-[4-(4-Chloro-1-ethyl-1H-pyrazole-3-carbonyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-ethanone;(4-Bromo-1-methyl-1H-pyrazol-3-yl)-{4-[2-(2-fluoro-phenyl)-ethyl]-piperazin-1-yl}-methanone;2-[(S)-4-(4-Bromo-1-methyl-1H-pyrazole-3-carbonyl)-3-methyl-piperazin ...

Подробнее
22-08-2013 дата публикации

INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF

Номер: US20130217726A1
Принадлежит:

The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions. 111-. (canceled)13. The method of claim 12 , where Ris NHCOR.14. The method of claim 12 , wherein Ris NHCOCalkyl claim 12 , NHCOphenyl or NHCObenzyl.15. The method of claim 12 , wherein A is selected from quinolinyl claim 12 , isoquinolinyl claim 12 , cinnolinyl claim 12 , quinazolinyl claim 12 , quinoxalinyl claim 12 , 1 claim 12 ,8-naphthyridyl claim 12 , phthalazinyl and pteridinyl claim 12 , each of which may be substituted or unsubstituted.16. The method of claim 12 , wherein Ris NHCOCalkyl and A is selected from quinolinyl claim 12 , isoquinolinyl claim 12 , cinnolinyl claim 12 , quinazolinyl claim 12 , quinoxalinyl claim 12 , 1 claim 12 ,8-naphthyridyl claim 12 , phthalazinyl and pteridinyl claim 12 , each of which may be substituted or unsubstituted.17. The method of claim 12 , wherein the compound is selected from:Ethyl 2-amino-7-hydroxy-4-quinolin-4-yl-4H-chromene-3-carboxylate,Ethyl 2-(acetylamino)-7-hydroxy-4-pyridin-3-yl-4H-chromene-3-carboxylate,Ethyl 2-amino-7-hydroxy-4-quinolin-3-yl-4H-chromene-3-carboxylate andEthyl 2-(acetylamino)-7-hydroxy-4-quinolin-3-yl-4H-chromene-3-carboxylateand pharmaceutically acceptable salts and solvates thereof.18. The method of claim 12 , wherein Ris CORand R-Rare selected from hydrogen claim 12 , acyl claim 12 , acyloxy claim 12 , carboxy and carboxyester. The present invention relates to novel compounds for use as inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said compounds. In particular, the compounds of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.The ...

Подробнее
22-08-2013 дата публикации

POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF

Номер: US20130217730A1
Принадлежит: IKERCHEM, S.L.

The present invention refers to compounds of formula (I): 2. Compound according to claim 1 , wherein Rand Rare hydroxyl or alkoxy group of linear or branched alkyl chain.3. Compound according to claim 1 , wherein Z is —(C—R)— and Rand Rare hydroxyl groups.4. Compound according to claim 3 , wherein Ris selected from the group consisting of —F claim 3 , hydroxyl claim 3 , —O—C-Calkyl claim 3 , nitro and cyano.5. Compound according to claim 1 , wherein Z is a nitrogen atom.6. Compound according to claim 5 , wherein Rand Rare an alkoxy group of linear or branched alkyl chain.7. Compound according to claim 1 , wherein each alkoxy group of linear or branched alkyl chain is independently selected from —O—C-Calkyl.12. (canceled)13. (canceled)14. A pharmaceutical composition that comprises at least a compound of formula (I) as defined in claim 1 , or a pharmaceutically acceptable solvate or a salt thereof claim 1 , and at least a pharmaceutically acceptable excipient.15. Method of treatment of a disease or condition selected from the group consisting of cancer claim 1 , diabetes claim 1 , age-related diseases or processes claim 1 , or neurodegenerative diseases claim 1 , said method comprising administering to a subject in need thereof a compound of . The present invention is related to new compounds derived from polysubstituted benzofuran rings, with new processes for their preparation and use thereof for the treatment and/or chemoprevention of cancer, diabetes, aging related diseases or processes, or neurodegenerative diseases.Emerging literature indicates that mechanisms of aging and associated malignancies are intricately down-regulated both by calorie restriction regimens and calorie restriction mimetics, such as plant polyphenols. Among these natural polyphenols, one of the most studied is resveratrol, which is believed to modulate the activity of SIRT1, either directly, or indirectly via modulation of the activity of other enzymes and proteins such as the AMP- ...

Подробнее
05-09-2013 дата публикации

INHIBITORS OF AkT ACTIVITY

Номер: US20130231378A1
Принадлежит: GlaxoSmithKline LLC

Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. 2. A compound of selected from:N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(4-bromo-1-methyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(4-bromo-1-methyl-1H-pyrazol-5-yl)-5-chloro-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(1-ethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(1,4-dimethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-ethyl-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(1,4-dimethyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5-ethyl-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(4-bromo-1-methyl-1H-pyrazol-5-yl)-5-ethyl-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(1,4-dimethyl-1H-pyrazol-5-yl)-5-ethyl-2-thiophenecarboxamide;N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl ...

Подробнее
12-09-2013 дата публикации

PYRROLIDINONE CARBOXAMIDE DERIVATIVES

Номер: US20130237514A1
Принадлежит: ChemoCentryx, Inc.

Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor. 3. A compound of claim 1 , wherein Ris methyl.4. A compound of claim 1 , wherein Ris methyl claim 1 , and Ris H or Calkyl.5. A compound of claim 1 , wherein Ris H or Calkyl claim 1 , Ris methyl claim 1 , and Ris H or Calkyl.6. A compound of claim 1 , wherein Ris CF.7. A compound of claim 1 , wherein Ris methyl and Ris CF.9. A compound of claim 8 , wherein Ris selected from the group consisting of —NRRand RRN—Calkyl.10. A compound of claim 9 , wherein Ris RRN—Calkyl.11. A compound of claim 9 , wherein Ris —NRR.12. A compound of claim 8 , wherein Rand Rare each methyl.13. A compound of claim 12 , wherein Ris selected from the group consisting of CF claim 12 , CN and cyclopropyl.14. A compound of claim 8 , wherein Ris mono- or di-(Calkyl)amino-Calkyl claim 8 , and Ris methyl.15. A compound of claim 14 , wherein Ris di(Calkyl)aminomethyl.16. A compound of claim 8 , wherein Rand Rare each methyl.18. A compound of claim 17 , wherein Ris H claim 17 , and Rand Rare each methyl.19. A compound of claim 18 , wherein Ris CF.21. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable excipient.221111111111111111111111111111111. The pharmaceutical composition of claim 21 , wherein the compound is a compound provided in claim 21 , B claim 21 , C claim 21 , D claim 21 , E claim 21 , F claim 21 , G claim 21 , H claim 21 , I claim 21 , J claim 21 , K claim 21 , L claim 21 , M claim 21 , N claim 21 , O claim 21 , P claim 21 , Q claim 21 , R claim 21 , S claim 21 , T claim 21 , U claim 21 , V claim 21 , W claim 21 , X claim 21 , Y claim 21 , Z claim 21 , AA claim 21 , BB claim 21 , CC claim 21 , DD claim 21 , EE and FF.23. A method of treating a disease or disorder in a mammal claim 1 , said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1 , for a period of time ...

Подробнее
19-09-2013 дата публикации

FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES

Номер: US20130244966A1
Принадлежит: CATABASIS PHARMACEUTICALS, INC.

The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate. 49-. (canceled)1113-. (canceled)1820-. (canceled)21. A pharmaceutical composition comprising the conjugate of and a pharmaceutically acceptable carrier.22. A pharmaceutical composition comprising the conjugate of and a pharmaceutically acceptable carrier.23. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.2429-. (canceled)30. A method of treating or preventing a viral infection claim 1 , the method comprising administering to a patient in need thereof an effective amount of a molecular conjugate of .31. A method of treating or preventing a viral infection claim 2 , the method comprising administering to a patient in need thereof an effective amount of the compound of .32. A method of treating or preventing a viral infection claim 3 , the method comprising administering to a patient in need thereof an effective amount of the compound of .3338-. (canceled)39. A method of treating or preventing a viral infection claim 14 , the method comprising administering to a patient in need thereof an effective amount of the compound of .40. The method of claim 39 , wherein the viral infection is hepatitis C.41. A method of treating or preventing a viral infection claim 15 , the method comprising administering to a patient in need thereof an effective amount of the compound of .42. The method of claim 41 , wherein the viral infection is HIV.43. A method of treating or preventing a viral infection claim 16 , the method comprising administering to a patient in need thereof an effective amount of the compound of claim 16 ,44. The method of claim 43 , wherein the viral infection is hepatitis B.4555-. (canceled) This application claims the benefit of U.S. ...

Подробнее
26-09-2013 дата публикации

ROSEOBACTICIDES AND USES THEREOF

Номер: US20130252815A1

Embodiments of the invention relate to compounds and methods for controlling algal growth, for example, in bodies of water or surfaces exposed to algae. Provided are compounds having algicidal activities and methods of use of these compounds as well as formulations and compositions comprising the compound having algicidal activities. 3. The compound of claim 2 , wherein Ris H or OR.4. The compound of claim 2 , wherein Ris H claim 2 , OH claim 2 , or OMe.8. The compound of claim 1 , wherein m is 1 and Ris OH claim 1 , SH claim 1 , or SSH.9. The compound of claim 1 , wherein X is O.11. The compound of claim 1 , wherein the compound has algicidal activity.12. The compound of claim 11 , wherein the algicidal activity has an LCof 0.01 μM to 35 μM.13Emiliana huxleyi.. The compound of claim 11 , wherein the algicide composition specifically kills the algae14. A composition comprising a compound of .15. An algicide formulation comprising a compound of .16. The algicide formulation of further comprising an algicide claim 15 , a herbicide claim 15 , a bactericide or a fungicide.17. A method of controlling algal growth in a body of water claim 1 , the method comprising adding to the water a sufficient amount of a compound claim 1 , composition or formulation of or a salt thereof to kill or inhibit growth of algae in the water.18. The method of claim 17 , wherein the body of water is selected from the group consisting of swimming pools claim 17 , aquaculture ponds claim 17 , freshwater ponds claim 17 , aquariums claim 17 , urban drainage systems and industrial cooling water systems.19. A method for protecting an industrial product against infestation and destruction by algae claim 1 , cyanobacteria and other photoautotrope microorganisms claim 1 , the method comprising incorporating in the industrial product an effective amount of a compound claim 1 , composition or formulation of or a salt thereof to kill and/or prevent algae growth.20. A material or industrial product ...

Подробнее
26-09-2013 дата публикации

Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Номер: US20130252919A1
Принадлежит: TUFTS UNIVERSITY

This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P 2 Y 6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

Подробнее
26-09-2013 дата публикации

5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS

Номер: US20130252974A1
Принадлежит: SANOFI

The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists. 2. The compound of claim 1 , wherein:R4 represents a hydrogen atom;W represents a halogen atom;Z represents a (C1-C4) alkylene group;either, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a monocyclic or polycyclic system selected from a (C3-C8) cycloalkyl group and a bridged tetracyclic group, wherein said monocyclic or polycyclic system is optionally substituted with one or more hydroxyl groups;either R3 represents a group C(O)R5, with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy group or a group NR6R7, with R6 and R7, independently of each other, representing a hydrogen atom or a (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkylsulfonyl, or haloalkyl group,{'sub': '2', 'or R3 represents a group CHXR8 in which X represents an oxygen atom and R8 represents a hydrogen atom or a (C1-C4) alkyl group,'}or R3 represents a nitrile group (CN).3. The compound of claim 1 , wherein:X represents a nitrogen atom and Y represents a nitrogen atom or —CR4-, in which R4 represents a hydrogen atom;A represents said fused aryl, unfused aryl, or heteroaryl group, wherein said aryl or heteroaryl group is optionally substituted with one or more groups selected from halogen atom, (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkoxy, and haloalkoxy;W represents a halogen atom;Z represents a (C1-C4) alkylene group; andeither, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a (C3-C8) cycloalkyl group optionally substituted with one or more hydroxyl groups or an adamantyl group;either R3 represents a group C(O)R5 with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy ...

Подробнее
26-09-2013 дата публикации

HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS

Номер: US20130253186A1
Принадлежит: Amgen Inc.

Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like. 11H-Benzo[d]imidazol-2-yl)(4-(3-(pyridine-4-yl)pyrazin-2-yloxy)piperidin-1-yl)methanone;1-(4-(3-(1-(1H-Benzo[d]imidazol-2-carbonyl)piperidin-4-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone;1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)piperidin-4-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone;1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone;1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone;1-(4-(3-(1-(1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone;1-(3-(2-(1-picolinoylazetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone;(R) and (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone;(1H-benzo[d]imidazol-2-yl)(3-(pyrazin-2-yloxy)azetidin-1-yl)methanone;(1H-benzo[d]imidazol-2-yl)(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)methanone;(R) and (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one;(1H-benzo[d]imidazol-2-yl)(3-((3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)methanone;benzyl 3-((3-chloropyrazin-2-yl)oxy)azetidine-1-carboxylate;tert-butyl 3-((3-((1r,4r)-4-hydroxycyclohexyl)pyridin-2-yl)oxy)azetidine-1-carboxylate;(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)methanone;(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone;benzyl 3-((3-(1-acetyl-4-hydroxypiperidin-4-yl)pyrazin-2-yl)oxy)azetidine-1-carboxylate;(1H-benzo[d]imidazol-2-yl)(3-((3- ...

Подробнее
03-10-2013 дата публикации

COMPOUNDS FOR ALZHEIMER'S DISEASE

Номер: US20130261118A1
Принадлежит:

The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). 2. The compound of claim 1 , whereinR6, R6′ and R10 are hydro,R7, R7′, R8 and R8′ are independently selected from at least one of hydro, alkyl and haloalkyl,R9 is alkyl or haloalkyl,R9′ is hydro,R20 is aryl or benzofuranyl, andR21 is heteroaryl.3. The compound of claim 1 , whereinR6, R6′, R7, R7′, R8, R9, R9′ and R10 are hydro,R8′ is 1,1-dimethylpropyl or trifluoromethyl,R20 is phenyl or 3,4-dichlorophenyl, andR21 is furan-2-carboxylic acid or thiazol-4-yl acetic acid.4. The compound of claim 1 , wherein the compound is selected from at least one of:5-[5-(1,1-dimethylpropyl)-2-phenyl-4,5,6,7-tetrahydro-indol-1-yl]-furan-2-carboxylic acid;5-[2-(3,4-dichloro-phenyl)-5-trifluoromethyl-4,5,6,7-tetrahydro-indol-1-yl]-furan-2-carboxylic acid; and{2-[5-(1,1-dimethylpropyl)-2-phenyl-4,5,6,7-tetrahydroindol-1-yl]-thiazol-4-yl}acetic acid.5. A composition comprising at least one compound of and a pharmaceutically acceptable excipient.7. The compound of claim 6 , whereinR6, R6′ and R10 are hydro,R7, R7′, R8 and R8′ are independently selected from at least one of hydro, alkyl and haloalkyl,R9 is alkyl or haloalkyl,R9′ is hydro,R20 is aryl or benzofuranyl, andR21 is heteroaryl.8. The compound of claim 6 , whereinR6, R6′, R7, R7′, R8, R9, R9′ and R10 are hydro,R8′ is 1,1-dimethylpropyl or trifluoromethyl,R20 is phenyl or 3,4-dichlorophenyl, andR21 is furan-2-carboxylic acid or thiazol-4-yl acetic acid.9. The compound of claim 6 , wherein the compound is selected from at least one of:5-[5-(1,1-dimethylpropyl)-2-phenyl-4,5,6,7-tetrahydro-indol-1-yl]-furan-2-carboxylic acid;5-[2-(3,4-dichloro-phenyl)-5-trifluoromethyl-4,5,6,7-tetrahydro-indol-1-yl]-furan-2-carboxylic acid; and{2-[5-(1,1-dimethylpropyl)-2-phenyl-4,5,6,7-tetrahydroindol-1-yl]-thiazol-4-yl}acetic acid.10. A composition ...

Подробнее
10-10-2013 дата публикации

Indole and indazole compounds that activate ampk

Номер: US20130267493A1
Принадлежит: PFIZER INC

The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Подробнее
10-10-2013 дата публикации

KINASE INHIBITORS

Номер: US20130267497A1
Принадлежит:

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. 2. The method of claim 1 , wherein the method is effective to treat a retinal ocular condition.3. The method of claim 1 , wherein the ocular condition is glaucoma.4. The method of claim 1 , wherein the ocular condition is proliferative vitreoretinopathy.5. The method of claim 1 , wherein the implant is placed in the posterior of the eye.6. The method of claim 1 , wherein the implant is placed in the eye with a trocar.7. The method of claim 1 , wherein the implant is placed in the eye with a syringe.8. The method of claim 1 , further comprising a step of administering a therapeutic agent in addition to the tyrosine kinase inhibitor to the patient. This application is a continuation of co-pending U.S. patent application Ser. No. 12/380,493, filed on Feb. 26, 2009, which is a continuation-in-part of U.S. patent application Ser. No. 10/837,361, filed on Apr. 30, 2004, now U.S. Pat. No. 7,771,742 the entire contents of both applications are hereby incorporated by reference.1. Field of the InventionThe present invention relates to novel compounds capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. The present invention is also directed to methods of regulating, modulating or inhibiting tyrosine kinases, whether of the receptor or non-receptor class, for the prevention and/or treatment of disorders related to unregulated tyrosine kinase signal transduction, including cell growth, metabolic, and blood vessel proliferative disorders.2. Description of the Related ArtProtein tyrosine kinases (PTKs) ...

Подробнее
24-10-2013 дата публикации

ISOINDOLONE DERIVATIVES

Номер: US20130281450A1
Принадлежит:

The present invention provides for compounds of formula (I) 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rare hydrogen; and Rand Rare each hydrogen.3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein Ris hydrogen.4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein Ris C-Calkyl.5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof claim 4 , wherein Ris methyl.6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , wherein Ris NRR claim 5 , —NR—SO—NR—C-Calkyl claim 5 , —NR—SO—NR—C-Chaloalkyl claim 5 , —NR—SO—C-Calkyl claim 5 , —NR—SO—C-Chaloalkyl claim 5 , SO—NRR claim 5 , SO—C-Calkyl claim 5 , —C(O)—NRR claim 5 , —C(O)—NH(C-Chaloalkyl) claim 5 , —C(O)—NH(C-Calkylene-heterocycloalkyl) claim 5 , —C(O)—NH(heteroaryl) claim 5 , NH—C(O)—C-Calkyl claim 5 , or NH—C(O)-heteroaryl.7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , wherein Ris NRR claim 6 , —NRSO—C-Calkyl claim 6 , or —NH—SO—C-Chaloalkyl.8. The compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , wherein Ris heteroaryl claim 5 , 9 to 12 membered bicyclic aryl claim 5 , or napthalen-1-yl.9. The compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , wherein Ris indolyl claim 5 , 1 claim 5 ,3-benzodioxolyl claim 5 , or benzimidazolyl.10. The compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein Ris X.13. The compound of claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , wherein n is 3.14. The compound of claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , wherein n is 2.15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , wherein Ris NRR claim 14 , —NR—SO—NR—C-Calkyl claim 14 , —NR—SO—NR—C-Chaloalkyl claim 14 , —NR—SO—C-Calkyl claim 14 , —NR—SO—C- ...

Подробнее
24-10-2013 дата публикации

Modulators of Muscarinic Receptors

Номер: US20130281476A1
Принадлежит:

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases. 171-. (canceled)73. The method according to claim 72 , wherein G is an optionally substituted bicyclic group of formula (III) in which ring B is absent.74. The method according to claim 73 , wherein Xis —(CH)—.75. The method according to claim 74 , wherein G is optionally substituted bicyclo[2.2.1]heptyl claim 74 , bicyclo[3.2.1]octyl claim 74 , bicyclo[3.3.1]nonyl claim 74 , bicyclo[2.2.2]octyl claim 74 , or bicyclo[2.2.1]heptanyl.76. The method according to claim 75 , wherein G is substituted with 1 to 2 substituents independently selected from Q claim 75 , and —C(O)—X-aliphatic claim 75 , where Xis absent claim 75 , —O— claim 75 , —NH— claim 75 , or —NQ- claim 75 , and the aliphatic group is optionally substituted with 1-3 substituents independently selected from Q.77. The method according to claim 73 , wherein Xis —N(Q)— or —N(C(O)—X-aliphatic) claim 73 , where Xis absent claim 73 , —O— claim 73 , —NH— claim 73 , or —NQ- claim 73 , and the aliphatic group is optionally substituted with 1-3 substituents independently selected from Q.78. The method according to claim 77 , wherein G is an optionally substituted tropane.79. The method according to claim 78 , wherein the tropane is substituted with Q claim 78 , or —C(O)—X-aliphatic claim 78 , where Xis absent claim 78 , —O— claim 78 , —NH— claim 78 , or —NQ- claim 78 , and the aliphatic group is optionally substituted with 1-3 substituents independently selected from Q.80. The method according to claim 78 , wherein the tropane is substituted at the tropane ring nitrogen atom with alkoxycarbonyl claim 78 , alkoxyalkoxycarbonyl claim 78 , heterocycloalkoxy carbonyl claim 78 , cycloalkoxycarbonyl claim 78 , alkoxyaryloxycarbonyl claim 78 , alkylaminocarbonyl claim 78 , haloalkoxy carbonyl claim 78 , ...

Подробнее
31-10-2013 дата публикации

ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES

Номер: US20130289004A1

A method of treating infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a 6. The method of claim 5 , wherein the acylamido is an amine substituted acylamido having the structure —NH—CO—(CH)—NH claim 5 , wherein x is an integer from 1-4.7. The method of claim 1 , wherein Ris aminosulfonamide claim 1 , and Ris a phenyl claim 1 , biphenyl claim 1 , naphthyl claim 1 , or anthracenyl group.9Staphylococcus. The method of claim 1 , wherein the is methicillin-resistant.10StaphylococcusStaphylococcus aureus.. The method of claim 1 , wherein the is11Staphylococcus aureus. The method of claim 10 , wherein the is methicillin-resistant.17. The pyrazole compound of claim 16 , wherein Ris methyl.18. The pyrazole compound of claim 16 , wherein Ris trifluoromethyl.21. The pyrazole compound of claim 20 , wherein Ris methyl.22. The pyrazole compound of claim 20 , wherein Ris trifluoromethyl.25. The pyrazole compound of claim 24 , wherein Ris methyl.26. The pyrazole compound of claim 24 , wherein Ris trifluoromethyl.29. The pyrazole compound of claim 28 , wherein Ris methyl.30. The pyrazole compound of claim 28 , wherein Ris trifluoromethyl. This application claims the benefit of provisional U.S. patent application Ser. No. 61/408,680 filed on Nov. 1, 2010 for ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES, the entire disclosure of which is fully incorporated herein by reference.The present invention was supported by Award Number UL1RR025755 from the National Center for Research Resources, funded by the Office of the Director, National Institutes of Health (OD) and supported by the NTH Roadmap for Medical Research. The Government has certain rights in this invention., a gram-positive bacterium, is one of the leading causes of hospital- and community-acquired infections in developed countries. It is estimated that is commensally associated with skin, skin glands and mucous membranes of 20-30% of the human population. can ...

Подробнее
31-10-2013 дата публикации

Isoquinoline Compounds And Methods For Treating HIV

Номер: US20130289027A1
Принадлежит: ViiV Healthcare UK Limited

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV). 134-. (canceled)3638-. (canceled)39. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound or salt as defined in .40. A method for treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses which method comprises administering to a mammal claim 35 , that has been diagnosed with said viral infection or is at risk of developing said viral infection claim 35 , a compound or salt as defined in .41. The method of claim 40 , wherein said virus is an HIV virus.42. The method according to claim 40 , further comprising administration of a therapeutically effective amount of one or more agents active against an HIV virus.43. The method according to claim 42 , wherein said agent active against HIV virus is selected from Nucleotide reverse transcriptase inhibitors; Non-nucleotide reverse transcriptase inhibitors; Protease inhibitors; Entry claim 42 , attachment and fusion inhibitors; Integrase inhibitors; Maturation inhibitors; CXCR4 inhibitors; and CCR5 inhibitors. This is a Patent Cooperation Treaty application and claims the benefit of U.S. Provisional Application No. 61/435,783, filed Jan. 24, 2011 and U.S. Provisional Application No. 61/510,534, filed Jul. 22, 2011, both of which are hereby incorporated by reference in their entireties.The present invention relates to substituted isoquinoline compounds, pharmaceutical compositions, and methods of use thereof for (i) inhibiting HIV replication in a subject infected with HIV, or (ii) treating a subject infected with HIV, by administering such compounds.Presently, long-term suppression of viral replication with ...

Подробнее
31-10-2013 дата публикации

QUINOXALINE COMPOUNDS AND USES THEREOF

Номер: US20130289041A1

Disclosed herein are compounds of formula (I) and methods of inhibiting IKKβ and the NF-κB signaling and mTOR pathways. 2. The compound of claim 1 , wherein each Ris independently selected from furanyl claim 1 , thiophenyl claim 1 , pyridinyl claim 1 , and phenyl.310.-. (canceled)11. The compound of claim 1 , wherein at least Ris methyl claim 1 , ethyl claim 1 , propyl claim 1 , or isopropyl.1216.-. (canceled)1922.-. (canceled)23. The compound of claim 1 , wherein X is alkoxy.2429.-. (canceled)30. The compound of claim 1 , wherein X is CF claim 1 , CHF claim 1 , CHF claim 1 , CCl claim 1 , CHCl claim 1 , CHCl claim 1 , CBr claim 1 , CHBr claim 1 , or CHBr.31. (canceled)32. The compound of claim 1 , wherein Ris alkyl.3340.-. (canceled)41. The compound of claim 1 , wherein Ris CF claim 1 , CHF claim 1 , CHF claim 1 , CCl claim 1 , CHCl claim 1 , CHCl claim 1 , CBr claim 1 , CHBr claim 1 , or CHBr.4245.-. (canceled)50. (canceled)51. A method comprising contacting a cell with the compound of in an amount effective to decrease activity of IKKβ.5255.-. (canceled)56. A method of inhibiting NFκB signaling pathway comprising contacting a cell with the compound of in an amount effective to inhibit the NFκB signaling pathway.57. (canceled)58. A method of inhibiting mTOR signaling pathway comprising contacting a cell with the compound of in an amount effective to inhibit the mTOR signaling pathway.59. (canceled)60. A method of treating a subject suffering from an IKKβ-dependent condition comprising administering to the subject a therapeutically effective amount of the compound of .61. (canceled)62. The method of claim 60 , wherein the condition is cancer claim 60 , diabetes claim 60 , an inflammatory disease claim 60 , or a neurological disorder.6372.-. (canceled)73. An electroluminescent device comprising the compound of .7475.-. (canceled)76. An organic electroluminescent device which comprises a cathode claim 1 , an anode claim 1 , and an organic thin film layer comprising ...

Подробнее
07-11-2013 дата публикации

ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS

Номер: US20130296309A1
Принадлежит:

The present invention provides a compound of formula I; 3. (canceled)7. (canceled)9. (canceled)10. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein A is CHR.11. The compound of claim 1 , or a pharmaceutically salt thereof wherein Ris Calkyl claim 1 , Ris H claim 1 , Ris H claim 1 , A is CHR claim 1 , Ris Calkyl or Ccycloalkyl claim 1 , p is 1 or 2.12. The compound of selected from:N-(cyclopropyl(5-(6-methoxynaphthalen-2-yl)pyridin-3-yl)methyl)ethanesulfonamide;N-(cyclopropyl(5-benzo-[1,3]-dioxol-5-yl-pyridin-3-yl)methyl)ethanesulfonamide;N-(cyclopropyl(5-(2,3-dihydro-benzofuran-5-yl)pyridin-3-yl)methyl)ethanesulfonamide;N-(cyclopropyl(5-(1H-indol-5-yl)pyridin-3-yl)methyl)ethanesulfonamide;N-(cyclopropyl(5-(1-methyl-1H-indol-5-yl)pyridin-3-yl)methyl)ethanesulfonamide;N-(cyclopropyl(5-naphtalen-1-yl-pyridin-3-yl)methyl)ethanesulfonamide;N-((5-(6-cyanonaphtthalen-2-yl)pyridin-3-yl)(cyclopropyl)methyl)ethane-sulfonamide;N-(cyclopropyl(5-(quinolin-6-yl)pyridin-3-yl)methyl)ethanesulfonamide;N-((5-(benzo[d]thiazol-5-yl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;N-((5-(benzofuran-5-yl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;or a pharmaceutically acceptable salt thereof.13. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more pharmaceutically acceptable carriers.14. A combination claim 1 , in particular a pharmaceutical combination claim 1 , comprising a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more therapeutically active agents selected from an HMG-Co-A reductase inhibitor claim 1 , an angiotensin II receptor antagonist claim 1 , angiotensin converting enzyme (ACE) Inhibitor claim 1 , a calcium channel blocker (CCB) claim 1 , a dual angiotensin converting enzyme/neutral ...

Подробнее
07-11-2013 дата публикации

1H-QUINAZOLINE-2,4-DIONES

Номер: US20130296332A1
Принадлежит:

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) 2. Compounds according to claim 1 , wherein{'sup': '1', 'sub': '3', 'Rrepresents CFor iso-Propyl and'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents (C-C)alkyl substituted by one to three substituents, the substituents being selected from the group consisting of halogen, nitro, cyano, HCO, (C-C)alkylcarbonyl, hydroxy, (C-C)alkoxy, (C-C)alkylcarbonyloxy, (C-C)alkoxycarbonyloxy, amino, (C-C)alkylamino, di(C-C)alkylamino, acylamino, (C-C)alkoxycarbonylamino, except trifluoromethyl or'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents heterocyclyl(C-C)alkyl substituted by one to three substituents, the substituents being selected from the group consisting of halogen, nitro, cyano, hydroxy, (C-C)alkoxy, (C-C)alkylcarbonyloxy, (C-C)alkoxycarbonyloxy, amino, (C-C)alkylamino, di(C-C)alkylamino, (C-C)alkoxycarbonylamino and the heterocyclyl consist of 3 to 11 ring atoms of which 1-3 ring atoms are hetero atoms or'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents phenyl substituted by one to three substituents, the substituents being selected from the group consisting of cyano, hydroxy, alkanediyl, alkenediyl, (C-C)alkoxy, (C-C)alkylcarbonyloxy, (C-C)alkoxycarbonyloxy, amino, (C-C)alkylamino, di(C-C)alkylamino, (C-C)alkoxycarbonylamino or'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents heterocyclyl optionally substituted by one to three substituents, the substituents being selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, (C-C)alkyl, hydroxy(C-C)alkyl, (C-C)alkoxyalkyl, amino(C-C)alkyl, (C-C)alkylamino(C-C)alkyl, di(C-C)alkylamino(C-C)alkyl, HCO, (C-C)alkylcarbonyl, (C-C)alkoxy, acyloxy, (C-C) ...

Подробнее
07-11-2013 дата публикации

2-Thiopyrimidinones

Номер: US20130296351A1
Принадлежит: PFIZER INC.

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Подробнее
14-11-2013 дата публикации

NEW COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODE PESTS

Номер: US20130303368A1
Принадлежит: MONSANTO TECHNOLOGY LLC

Compositions and processes for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include certain 2,5-substituted tetrazoles. 3. (canceled)1113-. (canceled)14. A nematicidal composition comprising a compound of at a concentration sufficient to reduce the viability of a parasitic nematode.15. (canceled)16. The nematicidal composition of wherein the composition comprises one or more of a fungicide claim 14 , a herbicide claim 14 , or another pesticide.17. (canceled)18. A coated seed wherein the coating comprises a compound of .19. A nematicidal composition comprising a compound of at a concentration sufficient to reduce the viability of a parasitic nematode.20. The nematicidal composition of wherein the composition comprises one or more of a fungicide claim 19 , a herbicide claim 19 , or another pesticide.21. A coated seed wherein the coating comprises a compound of .22. A method for control of unwanted nematodes claim 1 , the method comprising administering to a plant claim 1 , a seed claim 1 , or soil a composition comprising an effective amount of a compound of .23. A method for control of unwanted nematodes claim 6 , the method comprising administering to a plant claim 6 , a seed claim 6 , or soil a composition comprising an effective amount of a compound of .26. The method of wherein the compound is selected from the group consisting of:2-phenyl-5-(thiophen-2-yl)-2H-tetrazole,5-(furan-2-yl)-2-phenyl-2H-tetrazole,2-(4-chlorophenyl)-5-(thiophen-2-yl)-2H-tetrazole,2-(4-chlorophenyl)-5-(furan-2-yl)-2H-tetrazole,2-(4-chloro-2-methylphenyl)-5-(thiophen-2-yl)-2H-tetrazole,2-(4-chloro-2-methylphenyl)-5-(furan-2-yl)-2H-tetrazole,5-phenyl-2-(thiophen-2-yl)-2H-tetrazole, 2-(furan-2-yl)-5-phenyl-2H-tetrazole,5-(4-chlorophenyl)-2-(thiophen-2-yl)-2H-tetrazole,5-(4-chlorophenyl)-2-(furan-2-yl)-2H-tetrazole,5-(4-chloro-2-methylphenyl)-2-(thiophen-2-yl)-2H-tetrazole,5-(4-chloro-2-methylphenyl)-2-(furan-2-yl)-2H-tetrazole,and ...

Подробнее
14-11-2013 дата публикации

Triazole Compounds that Modulate HSP90 Activity

Номер: US20130303493A1
Принадлежит: Synta Pharmaceuticals Corp.

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound. 177-. (canceled)79. The compound of claim 78 , wherein the compound is selected from the group consisting of:5-(4-ethoxy-2-hydroxyphenyl)-4-(4-(morpholinomethyl)phenyl)-4H-1,2,4-triazole-3-carboxamide;5-(2-hydroxy-4-methoxyphenyl)-4-(4-(morpholinomethyl)phenyl)-4H-1,2,4-triazole-3-carboxamide;5-(2-hydroxy-4-prop oxyphenyl)-4-(4-(morpholinomethyl)phenyl)-4H-1,2,4-triazole-3-carboxamide;5-(2-hydroxy-4-isopropoxyphenyl)-4-(4-(morpholinomethyl)phenyl)-4H-1,2,4-triazole-3-carboxamide;5-(2,4-dimethoxyphenyl)-4-(4-(morpholinomethyl)phenyl)-4H-1,2,4-triazole-3-carboxamide;5-(2-hydroxy-4-isopropylphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(2-hydroxy-4-methylphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(4-hydroxy-3-isopropylphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(3-tert-butyl-4-hydroxyphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(4-hydroxy-3-propylphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(3-cyclopentyl-4-hydroxyphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(3-ethyl-4-hydroxyphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;5-(3-sec-butyl-4-hydroxyphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide; and5-(3-cyclohexyl-4-hydroxyphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazole-3-carboxamide;or pharmaceutically acceptable salts thereof.80. The compound of claim 78 , wherein the compound is selected from the group consisting of:5-(2-hydroxy-5-isopropyl-4-methoxyphenyl)-N-isopropyl-4-( ...

Подробнее
14-11-2013 дата публикации

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Номер: US20130303535A1
Принадлежит:

The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The compound is represented by formula (1) or a pharmaceutically acceptable salt thereof wherein Ris a hydrogen atom or the like, L is a single bond, —O— or the like, Ris a phenyl group or the like, X is a carbon atom or a nitrogen atom, and R, R, R, R, Rand Rare each independently a substituted or unsubstituted alkyl group or the like: 4. The method of claim 1 , wherein Ris a substituted or unsubstituted phenyl group claim 1 , or a pharmaceutically acceptable salt thereof.5. The method of claim 1 , wherein Ris a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms claim 1 , a substituted or unsubstituted 3- to 8-membered cycloalkyl group claim 1 , a substituted or unsubstituted 4- to 8-membered saturated aliphatic heterocyclic group claim 1 , or a substituted or unsubstituted 5- to 10-membered unsaturated aliphatic heterocyclic group claim 1 , or a pharmaceutically acceptable salt thereof.6. The method of claim 1 , wherein Rand Rare each independently a hydrogen atom claim 1 , a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms claim 1 , a haloalkyl group having 1 to 6 carbon atoms claim 1 , a substituted or unsubstituted 3- to 8-membered cycloalkyl group claim 1 , a substituted or unsubstituted 4- to 8-membered saturated aliphatic heterocyclic group claim 1 , or a substituted or unsubstituted 5- to 10-membered unsaturated aliphatic heterocyclic group claim 1 , or Rand Rare optionally bonded to form claim 1 , together with the nitrogen atom that they are bond to claim 1 , a substituted or unsubstituted 4- to 8-membered saturated nitrogen-containing aliphatic heterocycle claim 1 , or a substituted or unsubstituted 5- to 10-membered unsaturated nitrogen-containing aliphatic heterocycle (the saturated or unsaturated nitrogen-containing ...

Подробнее
14-11-2013 дата публикации

BENZOPYRONE ESTROGEN RECEPTOR REGULATOR

Номер: US20130303544A1
Автор: Ding Hongxia, Li Jin, Meng Kun
Принадлежит: BEIJING SHENOGEN PHARMA GROUP LTD.

The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc. 109. The compound of - is selected from the group consisting of:2-(3-fluoro-4-methoxyphenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3,5-difluorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3-fluorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3,4-difluorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3-fluoro-4-chlorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3-fluoro-4-trifluoromethylphenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-fluorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3-chloro-4-fluorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-fluoro-3-methoxyphenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-chlorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-chloro-3-methylphenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(3,4-dichlorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-chloro-3-fluoromethylphenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(2-fluoro-4-chlorophenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-trifluoromethylphenyl)-5,7-dihydroxy-3-methoxy-6,8-di(3-methyl-2-buten-1-yl)-4H-benzopyran-4-one;2-(4-methylphenyl)-5,7-dihydroxy-3- ...

Подробнее
21-11-2013 дата публикации

PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR

Номер: US20130310419A1
Принадлежит: Lupin Limited

The present invention is related to pyrrole derivatives of formula I as the modulators of nicotinic acetylcholine receptors particularly the α7 subtype. The invention includes pyrrole derivatives, analogues, their prodrugs, their isotopes, their metabolites, pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them. Owing to the modulatory activity of the pyrrole derivatives on the nicotinic acetylcholine receptors, the invention finds application in the prophylaxis and therapy of disorders encompassing the involvement of cholinergic transmission in the central and peripheral nervous system. The invention relates to the ability of pyrrole derivatives to modulate the cholinergic transmission and efficacy of the endogenous neurotransmitter ACh thorough the nicotinic acetylcholine receptors particularly the α7 subtype. 2. The compound of formula I as claimed in claim 1 , wherein Ris selected as methyl.3. The compound of formula I as claimed in claim 1 , wherein Ris selected from ethyl and ethoxy.4. The compound of formula I as claimed in claim 1 , wherein Ris selected from hydrogen and methyl.7. The compound of formula I as claimed in claim 1 , wherein the compound is selected from—4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;4-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;4-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3,5-dimethyl-4-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;Ethyl 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,4-dimethyl-1-(4-sulfamoylphenyl)-1H-pyrrole-3-carboxylate;4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl) ...

Подробнее
21-11-2013 дата публикации

Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors

Номер: US20130310562A1
Принадлежит: GlaxoSmithKline LLC

A pharmaceutical formulation comprising the compound of formula 2. The formulation of claim 1 , wherein said unit dose is a tablet. This application is a continuation of Ser. No. 12/691,784 filed on Jan. 22, 2010 which is a continuation of Ser. No. 11/752,582 filed on May 23, 2007, now abandoned, which is a continuation of U.S. Ser. No. 10/342,810 filed on Jan. 15, 2003, now abandoned, which is a continuation of U.S. Ser. No. 09/582,746 filed on Jun. 30, 2000, which issued as U.S. Pat. No. 6,727,256 on Apr. 27, 2004 and which was the national phase application of international application PCT/EP99/00048, filed Jan. 8, 1999, which claims priority to GB9800569, filed Jan. 12, 1998 in the UK, the contents of which is incorporated herein by reference.The present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to quinoline, quinazoline, pyridopyridine and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.Protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth and differentiation (A. F. Wilks, Progress in Growth Factor Research, 1990, 2, 97-111; S. A. Courtneidge, Dev. Supp.l, 1993, 57-64; J. A. Cooper, Semin. Cell Biol., 1994, 5(6), 377-387; R. F. Paulson, Semin. Immunol., 1995, 7(4), 267-277; A. C. Chan, Curr. Opin. Immunol., 1996, 8(3), 394-401). Protein tyrosine kinases can be broadly classified as receptor (e.g. EGFr, c-erbB-2, c-met, tie-2, PDGFr, FGFr) or non-receptor (e.g. c-src, Ick, zap70) kinases. Inappropriate or uncontrolled activation of many of these kinase, i.e. aberrant protein tyrosine kinase activity, for example by over-expression or mutation, has been shown to result in uncontrolled cell growth.Aberrant activity of protein tyrosine kinases, such as c-erbB-2, c-src, c-met, EGFr ...

Подробнее
28-11-2013 дата публикации

Slow Release of Organoboronic Acids in Cross-Coupling Reactions

Номер: US20130317223A1

A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: 1. A method of performing a chemical reaction , comprising:reacting in a reaction mixturea compound selected from the group consisting of an organohalide and an organo-pseudohalide, and {'br': None, 'sup': '1', 'R—B-T\u2003\u2003(I),'}, 'a protected organoboronic acid represented by formula (I) [{'sup': '1', 'Rrepresents an organic group,'}, 'T represents a conformationally rigid protecting group,', {'sup': '3', 'B represents boron having sphybridization,'}, 'a corresponding unprotected organoboronic acid is unstable by the boronic acid neat stability test, and', {'sub': 'B', 'the reaction mixture further comprises a base having a pKof at least 1, and a palladium catalyst; and'}], 'where'}forming a cross-coupled product in the reaction mixture.2. The method of claim 1 , where Rcomprises a 2-heterocyclic group.3. The method of claim 2 , where Ris selected from the group consisting of a 2-furyl group claim 2 , a 2-benzofuryl group claim 2 , a 2-thiophenyl group claim 2 , a 4-(4′-methylthiophene)-thiophenyl group claim 2 , a 2-(N-butoxycarbonyl-pyrollyl) group claim 2 , and a 2-(N-phenylsulfonate-indolyl) group.4. The method of claim 1 , where Rcomprises a vinyl group.5. The method of claim 1 , where Rcomprises a cyclopropyl group.6. The method of claim 1 , where{'sup': '1', 'claim-text': {'br': None, 'sup': 2', '3, 'sub': 'm', 'Y—R—(R)—\u2003\u2003(III),'}, 'Ris a group represented by formula (III)where Y represents a halogen group or a pseudohalogen group;{'sup': '2', 'Rrepresents an aryl group;'}{'sup': '3', 'Rcomprises at least one group selected from the group consisting of an alkyl group, a heteroalkyl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, an aryl group, and a heteroaryl group; ...

Подробнее
05-12-2013 дата публикации

1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS

Номер: US20130324550A1
Принадлежит: THERAVANCE, INC.

The invention relates to compounds of formula I: 24-. (canceled)5. The compound of claim 1 , where Ris hydrogen or halo.6. The compound of claim 1 , where Ris hydrogen or halo.7. The compound of claim 1 , where Ris hydrogen or halo.8. The compound of claim 1 , where Ris hydrogen or halo.9. The compound of claim 1 , where Ris hydrogen or halo.10. The compound of claim 1 , where a is 0.11. The compound of claim 1 , where HAr is selected from 2-pyridyl claim 1 , 3-pyridyl claim 1 , 4-pyridyl claim 1 , 5-pyridyl claim 1 , 2-furyl claim 1 , 4-furyl claim 1 , 2-thienyl claim 1 , 3-thienyl claim 1 , and 4-thienyl.12. The compound of claim 11 , where Rare independently hydrogen or halo.1314-. (canceled)16. The method of claim 15 , where a is 0; HAr is selected from 2-pyridyl claim 15 , 3-pyridyl claim 15 , 4-pyridyl claim 15 , 5-pyridyl claim 15 , 2-furyl claim 15 , 4-furyl claim 15 , 2-thienyl claim 15 , 3-thienyl claim 15 , and 4-thienyl; and Rare independently hydrogen or halo.17. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.1820-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/316,090, filed on Mar. 22, 2010; the entire disclosure of which is incorporated herein by reference.1. Field of the InventionThe present invention relates to 1-(2-phenoxymethylheteroaryl)piperidine and 1-(2-phenoxymethylheteroaryl)piperazine compounds having activity as serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat a pain disorder, such as neuropathic pain, and other ailments.2. State of the ArtPain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (International Association for the Study of Pain (IASP), Pain Terminology ...

Подробнее
05-12-2013 дата публикации

PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF

Номер: US20130324566A1
Принадлежит:

The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided. 2. Pyrimidine compounds according to for use as dual inhibitors of NO and prostaglandin E2 production.3. Pyrimidine compounds according to for use in the treatment of diseases which are induced or the severity of which is potentiated by the overproduction of NO and/or prostaglandin E2 claim 1 , particularly in the treatment of inflammatory or cancer diseases or as anti-angiogenic claim 1 , immunomodulation claim 1 , antiproliferative or antitumor substances.4. Pyrimidine compounds according to which contain at least one deuterium atom.6. Method of preparation of pyrimidine compounds of general formula I according to carrying 2-formamido group claim 1 , characterized in that the corresponding 2-[(dimethylamino)-methylene] derivative is selectively hydrolyzed in organic solvent in the presence of water claim 1 , silica gel and acetic acid at a temperature in the range from 10 to 30° C.7. Pharmaceutical composition claim 1 , characterized in that it contains pyrimidine compounds of general formula I according to or its pharmaceuticaly acceptable salts claim 1 , and at least one pharmaceutical carrier claim 1 , excipient and/or diluent.8. Pharmaceutical composition according to for use in the treatment of diseases which are induced or the severity of which is potentiated by the overproduction of NO and/or prostaglandin E2 claim 7 , particularly ...

Подробнее
12-12-2013 дата публикации

Inhibitors of Retroviral Replication

Номер: US20130331414A1
Принадлежит:

Methods for preventing or treating retroviral infection, such as human immunodeficiency virus, in vivo utilize transcriptional inhibitory compounds. These include cortistatin A and analogs of the cortistatin family. 1. A method of preventing viral infection or treating a viral infection in a patient , comprising:administering to the patient a therapeutically effective amount of an inhibitor of retroviral transcription wherein the inhibitor inhibits retroviral transcription as compared to a control; and,preventing viral infection or treating a viral infection in the patient,wherein the inhibitor of retroviral transcription comprises cortistatins, cortistatin derivatives, analogs, substituted cortistatins or salts thereof.2. The method of claim 1 , wherein the retroviral viral infection is a lentivirus.3. The method of claim 2 , wherein the lentivirus is a human immunodeficiency virus (HIV).4. The method of claim 1 , wherein the inhibitor of retroviral transcription inhibits function or activity of a Trans-Activator of Transcription (Tat) claim 1 , a molecule associated with Trans-Activator of Transcription (Tat) claim 1 , a molecule associated with Transactivation Responsive element (TAR) a Transactivation Responsive element (TAR) and/or interaction between a Trans-Activator of Transcription (Tat) and a Transactivation Responsive element (TAR) claim 1 , DNA-PK or combinations thereof.511-. (canceled)14. The method of claim of claim 1 , wherein the cortistatin analog is a didehydro-cortistatin A (dCA).15. The method of claim 1 , wherein the cortistatin is cortistatin A.16. The method of claim 1 , further comprising administering to a patient therapeutically effective amount of one or more anti-retroviral drugs.17. The method of claim 16 , wherein the antiviral drugs comprise one more of: fusion inhibitors (FIs) claim 16 , nucleoside reverse transcriptase inhibitors (NRTIs) claim 16 , non-nucleoside reverse transcriptase inhibitors (NNRTIs) claim 16 , nucleotide ...

Подробнее